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 “This is how you do it: 
You sit down at the keyboard and you 
put one word after another until it is 
done. It is that easy, and that hard.” 
-Neil Gaiman 
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ABSTRACT 
Intestinal permeability is a key measure of gastrointestinal function and studies 
have associated increased intestinal permeability with several different 
pathologies. Clinically, increased intestinal permeability could contribute to 
disease pathophysiology by allowing unwanted substances to enter circulation 
and stimulate inflammatory processes. Thus, a better understanding of the 
factors and mechanisms that affect intestinal permeability could offer new 
insights on how to manage these diseases and disorders. 
The aim of this thesis was to investigate intestinal permeability changes under 
three separate settings. Chemotherapy-induced gastrointestinal toxicity is a 
major complication of cancer treatment and we examined if measuring 
intestinal permeability to iohexol could be used to assess the severity of this 
complication. We also hypothesized that chemotherapeutics affect the 
composition of intestinal microbiota and the global metabolome and studied 
how these alterations relate to increased intestinal permeability. In another 
study setting, we investigated whether intestinal permeability changes explain 
individual’s susceptibility to gastrointestinal symptoms during exercise. Finally, 
we treated intestinal tissue segments with a deoxycholic acid (DCA) 
concentration associated with high-fat feeding and examined the mechanisms 
by which it affects macromolecular permeability. 
Our results show that commonly used chemotherapeutics, running at a 
challenging pace for 90 min, and DCA concentration associated with high-fat 
feeding increase intestinal permeability. The observed increase in intestinal 
permeability after chemotherapy also correlated with the severity of 
gastrointestinal toxicity. Chemotherapy-induced gastrointestinal toxicity was 
also associated with unfavorable changes in the composition of intestinal 
microbiota which may play a role in the pathophysiology of intestinal 
complications during chemotherapy. Running-induced increase in intestinal 
permeability seems to result from intestinal ischemia but it did not explain the 
occurrence of gastrointestinal symptoms during the running test. The DCA-
ABSTRACT 
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induced increase in macromolecular permeability appears to stem from direct 
interaction with the mucosa. However, we also observed evidence that DCA 
affects the intestine via a neural mechanism. Overall, these results demonstrate 
how different stressors can impair intestinal barrier function and possibly lead 
to various symptoms and complications.     
INTRODUCTION 
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1 INTRODUCTION 
The gastrointestinal tract forms one of the largest epithelial barriers between 
the outside world and the host. The intestinal epithelium acts as a gate-keeper 
that must grant passage to nutrients while limiting the flux of noxious 
substances. The proper function of this double duty requires several 
mechanisms that together uphold intestinal homeostasis.  
Intestinal permeability is one of key measures of intestinal homeostasis and 
alterations in intestinal permeability have been associated with multiple 
pathologies, such as inflammatory bowel diseases (IBD) (Michielan and D’Incà, 
2015), irritable bowel syndrome (IBS) (Camilleri et al., 2012), different 
autoimmune diseases (Bischoff et al., 2014; Vaarala, 2013), obesity, and obesity-
related diseases (Teixeira et al., 2012a). These observations have led to 
investigations about the factors and mechanisms that affect intestinal 
permeability. In addition, studies have tried to elucidate the causality between 
increased intestinal permeability and the pathophysiology of these diseases. 
Overall, these studies have revealed that abnormal intestinal permeability is a 
fundamental feature of disrupted intestinal homeostasis and measuring 
intestinal permeability could provide a useful tool for assessing changes in 
gastrointestinal function. 
In this thesis, we investigated changes in intestinal permeability in three 
different study setting. First, we examined how chemotherapeutics affect 
intestinal permeability and whether intestinal permeability changes reflect the 
severity of gastrointestinal toxicity observed after chemotherapy. We also 
studied the associations between intestinal permeability and metabolic and 
microbial changes following the administration of chemotherapeutics. Next, we 
probed the connection between intestinal permeability and gastrointestinal 
symptoms during exercise. Finally, we investigated the mechanisms by which 
deoxycholic acid (DCA) affects the intestinal barrier. 
REVIEW OF LITERATURE 
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2 REVIEW OF LITERATURE 
2.1 Intestinal barrier function 
2.1.1 Components of the intestinal barrier 
The intestinal epithelium forms a dynamic barrier between the outside 
environment and the host. This barrier has a challenging task of absorbing the 
necessary nutrients while simultaneously prohibiting the passage of harmful 
substances. The latter purpose is usually referred to as intestinal barrier 
function and the intestine has multiple mechanisms in place to achieve this 
function (for review, see Martini et al., 2017). The mechanisms of intestinal 
barrier function are summarized in Figure 1. 
Firstly, the rapid turnover of intestinal cells requires that the epithelium must 
constantly be replenished by intestinal stem cells. The continuous 
differentiation of intestinal stem cells into intestinal epithelial cells is vital for 
normal intestinal homeostasis and for sustaining intestinal integrity. The 
intestinal stem cells can differentiate into four types of cells: goblet cells, Paneth 
cells, enteroendocrine cells or enterocytes. Each of these cell types plays a role 
in maintaining the intestinal barrier function (for review, see Goll and 
Granlund, 2015).  
The first line of defense consists of secretory products. Epithelial goblet cells 
secrete mucins that form a thick, viscous layer of mucus which prevents 
pathogens from directly contacting the epithelia (Frey et al., 1996). Paneth cells 
produce antimicrobial agents such as defensins that help to clear pathogens 
from the epithelial environment (Goll and Granlund, 2015). Additionally, 
enteroendocrine cells secrete serotonin and other immunomodulatory 
neuropeptides (Worthington, 2015). Serotonin also regulates intestinal motility 
and secretion, events that flush away potentially noxious substances from the 
intestinal lumen.  
REVIEW OF LITERATURE 
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The most important intestinal defense mechanism is the physical barrier 
comprising of intestinal enterocytes and of the junctional complexes that link 
adjacent enterocytes together (Turner, 2009). The junctional complex consists 
of desmosomes, adherens junction, and tight junctions. Desmosomes and 
adherens junctions provide the mechanical linkage between enterocytes 
whereas tight junctions seal the intercellular space and regulate solute flux 
through the paracellular pathway (for review, see Groschwitz and Hogan, 2009). 
This unique function makes tight junctions pivotal for maintaining the mucosal 
integrity and changes or defects in their composition compromises the 
intestinal barrier function (Marchiando et al., 2010a).  
Underneath the epithelial layer resides the gut-associated lymphoid tissue 
(GALT) which provides the last line defense against invading pathogens. 
Microfold cells (M-cells) are specialized epithelial cells that uptake luminal 
antigens and present them to submucosal dendritic cells (for review, see Ohno, 
2016). Dendritic cells can also sample antigens straight from the lumen by 
extending their dendrites through the intercellular space between enterocytes. 
Dendritic cells present the collected antigens further to T-cells and B-cells 
inducing their activation and differentiation (Ohno, 2016). The B-cells 
differentiate to plasma cells that secrete immunoglobulin A (sIgA) into the 
intestinal lumen. sIgA is the most abundant intestinal antibody and it 
effectively blocks pathogens from binding to the epithelium (Mantis et al., 2011). 
In addition to the body’s own mechanisms, the intestinal lumen harbors a 
naturally occurring ecosystem of numerous microbial species. These microbes 
consume nutrients, compete for living space, and secrete antimicrobial 
substances. All these mechanisms prevent the colonization of pathogenic 
microbes and thus contribute to the intestinal barrier function (for review, see 
Yu et al., 2012). 
REVIEW OF LITERATURE 
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Figure 1. Schematic illustration of the different cell types in the 
intestinal epithelium and of the several mechanisms that 
contribute to intestinal barrier function (modified from Martini et 
al., 2017; and Ohno, 2016) 
 
2.1.2 Pathways of permeability 
Transepithelial passage of solutes across the intestinal epithelium occurs via 
two possible routes: the transcellular pathway and the paracellular pathway 
(Figure 2). The transcellular pathway refers to the energy-dependent and 
specific carrier-facilitated process of transporting nutrients, electrolytes, and 
other molecules through the cell membranes. In contrast, paracellular 
permeation happens between the epithelial cells and it is driven by passive 
movement of solutes against an electrochemical or concentration gradient 
(Groschwitz and Hogan, 2009).  
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Physically, epithelial permeability can be defined by the epithelium’s ability to 
resist electric current. This measure is called transepithelial resistance (TER) 
and the total TER value of an epithelium is the sum of transcellular and 
paracellular resistance (Figure 2). Considering that epithelial cell membranes 
have high resistances that remain relatively constant across body’s different 
epithelia, the paracellular resistance determines the overall TER value of given 
epithelium (Anderson and Van Itallie, 2009). Theoretically, TER values are 
inversely related to epithelial permeability: low TER values indicate a more 
permeable epithelium and vice versa. Functionally, the relevance of epithelial 
TER values connects to the purpose of individual epithelium. The intestinal 
epithelia are absorptive and secretory epithelia and thus have relatively low TER 
values (Anderson and Van Itallie, 2009) and subsequently high paracellular 
permeability. This makes paracellular permeability the main determinant of 
intestinal permeability (Turner, 2009) and the term intestinal permeability 
usually applies exclusively to paracellular permeability. 
 
  
Figure 2. Solutes can cross the intestinal epithelium either 
transcellularly or paracellularly. Transepithelial resistance refers 
to the epithelium’s ability to resist electric current and it is the sum 
of transcellular (RTrans) and paracellular (RPara) resistance 
(modified from Anderson and Van Itallie, 2009) 
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More detailed analyses of the paracellular pathway have revealed two distinct 
courses for paracellular permeation: the pore pathway and the leak pathway (for 
review, see Shen et al., 2011). The pore pathway selectively permits the passage 
of molecules based on their charge and size with molecules larger than 10 Å not 
allowed to pass (Anderson and Van Itallie, 2009; France and Turner, 2017). The 
leak pathway has a lower capacity than the pore pathway and exhibits no 
charge-selectivity but it grants translocation to molecules with sizes up to 125 Å 
(France and Turner, 2017). Evidence suggests that these two pathways are 
spatially arranged along the crypt-villus axis so that paracellular permeability 
increases towards the crypt (Fihn et al., 2000; Shen et al., 2011). Physiologically, 
this configuration makes sense because it would allow the flux of ions and small 
molecules at the villous tips on the epithelial surface (i.e. the pore pathway) and 
restrict the paracellular passage of larger molecules to the crypts far from 
luminal contents (i.e. the leak pathway). Additionally, the permeability of pore 
and leak pathway can be regulated independently (Anderson and Van Itallie, 
2009; Shen et al., 2011) but it is not entirely clear how the interplay between 
these two pathways contributes to overall intestinal permeability.  
2.1.3 Tight junctions 
Tight junction is the most apical junctional complex connecting adjacent 
epithelial cells and it controls the paracellular flow of solutes through the 
intestinal epithelia. This makes tight junctions key moderators of not just 
intestinal permeability but also of the whole transepithelial transport (Turner, 
2009).  
Tight junctions are dynamic networks of over 50 different proteins with specific 
adaptor proteins connecting the actin cytoskeleton to the cell-membrane 
spanning proteins of the junctional complex (Ulluwishewa et al., 2011). The 
transmembrane part of the junctional complex includes five families of 
proteins: occludin, claudins, junctional adhesive molecules (JAMs), coxsackie 
virus and adenovirus receptor (CAR), and tricellulin. JAMs and CAR span the 
cell membrane only once whereas occludin, claudins, and tricellulin are tetra-
REVIEW OF LITERATURE 
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span proteins creating four transmembrane and two intracellular domains 
(Ulluwishewa et al., 2011). These intracellular domains anchor the 
transmembrane proteins to the cell’s actomyosin ring via cytosolic scaffold 
proteins, such as zonula occludens (ZO) proteins (Figure 3) (Suzuki, 2013). How 
these individual components and their interactions affect the function of tight 
junctions is briefly summarized below. 
Occludin was the first identified transmembrane tight junctional protein 
(Furuse et al., 1993) but initial reports showed that occludin knockdown does 
not have detrimental effects to the intestinal barrier function (Saitou et al., 1998; 
Schulzke et al., 2005). However, subsequent studies have revealed that silencing 
occludin expression in intestinal epithelial cells leads to increased paracellular 
flux of macromolecules (Al-Sadi et al., 2011a; Buschmann et al., 2013). These 
results suggest that occludin may mainly regulate the leak pathway with limited 
effects on the pore pathway. Silenced occludin expression also modifies the 
expression of other tight junctional proteins, most notably claudins (Al-Sadi et 
al., 2011a; Buschmann et al., 2013). Additionally, occludin phosphorylation 
controls the interaction between occludin and ZO-1 and thus can affect the 
properties of tight junctions (Groschwitz and Hogan, 2009). 
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Figure 3. Schematic illustration of the tight junction connecting 
two enterocytes together. Transmembrane proteins occludin, 
claudins, junctional adhesive molecules (JAMs), and coxsackie 
virus and adenovirus receptor (CAR) interact with cytosolic zonula 
occludens -proteins 1-3 (ZO1/2/3) that anchor the junctional 
complex to the actin cytoskeleton. Tricellulin forms linkage 
between three adjacent enterocytes and localizes to tricellular 
junctions (modified from Ulluwishewa et al., 2011). 
 
Claudins are a multiprotein family with humans expressing at least 26 different 
claudin isoforms (for review, see Garcia-Hernandez et al., 2017). These isoforms 
display different permeability properties which has led to the categorization of 
claudins as either barrier-enhancing or pore-forming. Pore-forming claudins, 
such as claudin-2 and claudin-10, create charge-selective channels that control 
the paracellular flux of ions and water (Anderson and Van Itallie, 2009). In 
contrast, barrier-enhancing claudins make tight junctions less permeable to 
certain ions. The fact that different claudin isoforms demonstrate charge-
specificity has raised the hypothesis that claudins are important regulators of 
the pore pathway (Anderson and Van Itallie, 2009). Indeed, studies on 
transgenic mice have revealed the vital role claudins play in regulating epithelial 
barrier homeostasis (Garcia-Hernandez et al., 2017). For example, claudin-1-/- 
mice die at birth due to skin barrier defects (Furuse et al., 2002) and           
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claudin-7-/- mice exhibit mucosal ulcerations and intercellular gaps in the 
intestine (Ding et al., 2012). Also, intestinal claudin-7 deletion results in 
increased colonic permeability to small solutes (Tanaka et al., 2015). 
Interestingly, in humans the expression of claudin isoforms reflects their 
permeability properties. In the intestinal tract, the expression of barrier-
enhancing claudins increases along the proximal-distal axis (Garcia-Hernandez 
et al., 2017; Lameris et al., 2013) which makes sense considering the distinct 
functions of small and large intestine (Martini et al., 2017). However, although 
the simple divide to barrier-enhancing and pore-forming claudins provides a 
useful framework to assess the function of individual claudins, the properties of 
tight junctions are always a combination of different claudin isoforms and their 
interactions (Garcia-Hernandez et al., 2017). Additionally, epithelial claudin 
expression, translocation, and modification is under constant regulation which 
further affects the permeability of tight junctions (Garcia-Hernandez et al., 
2017). 
JAMs and CAR are part of a larger family of proteins belonging in the 
immunoglobulin superfamily and they have a single transmembrane spanning 
domain. In addition to CAR, the intestinal epithelia express two JAM isoforms: 
JAM-A and JAM-4 (Suzuki, 2013). Overall, our understanding of their role in 
tight junctional regulation is lacking. JAM-A KO mice exhibit increased 
intestinal permeability and enhanced susceptibility to chemically-induced 
colitis compared to wild-type litter mates (Laukoetter et al., 2007). On the other 
hand, inactivation of the Car gene causes multiple phenotypes in adult mice but 
does not compromise the structure of intestinal tight junctions (Pazirandeh et 
al., 2011). 
Tricellulin localizes in tight junctions between three enterocytes and it seems 
to regulate macromolecular flux through the tricellular junctions (France and 
Turner, 2017). However, the regulation of tricellular junctions in the context of 
intestinal permeability warrants more research. 
REVIEW OF LITERATURE 
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ZO protein family of three proteins, ZO-1, ZO-2, and ZO-3, comprises of 
cytosolic scaffolding proteins that connect the transmembrane tight junction 
proteins to the actin cytoskeleton. ZO-1 and ZO-2 are crucial for normal 
development as ZO-1-/- and ZO-2-/- mice die already at embryonic state (France 
and Turner, 2017). In vitro, simultaneous silencing of ZO-1 and ZO-2 expression 
results in complete lack of tight junctions and increased paracellular flux 
(Umeda et al., 2006). Based on this and other evidence, the current 
understanding is that ZO proteins are necessary for the correct assembly of tight 
junctions (Suzuki, 2013). 
In addition to tight junctional proteins, the paracellular pathway is regulated 
by several intracellular signaling proteins. Intracellular proteins, such as myosin 
light chain kinase (MLCK), protein kinase C (PKC), mitogen-activated protein 
kinases (MAPK), and the Rho family of GTPases, facilitate signals between the 
transmembrane proteins and the actin cytoskeleton and thus regulate the 
properties of tight junctions (Ulluwishewa et al., 2011). The MLCK pathway is 
perhaps the best characterized example of intracellular regulation of tight 
junctional permeability with multiple studies reporting increased paracellular 
permeability via MLCK-mediated actin cytoskeleton reorganization (Shen, 
2012). 
2.1.4 Intestinal permeability as a measure of functionality 
In the context of intestinal epithelium, it is appropriate to distinguish between 
intestinal barrier function and intestinal permeability, two terms which are 
frequently used interchangeably. Intestinal barrier function refers to the 
epithelium’s task of prohibiting the entry of harmful substances from the gut 
lumen whereas intestinal permeability can be defined as a measurable feature 
of intestinal barrier function (Bischoff et al., 2014). In theory, defects in any of 
the elements forming the intestinal barrier may result in alterations in intestinal 
permeability. Considering the vast literature associating increased intestinal 
permeability and different diseases, information about the factors and 
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mechanisms that modulate the intestinal barrier is vital for our understanding 
of normal intestinal homeostasis and disease pathogenesis.   
To summarize, multiple structures and mechanisms form 
the intestinal barrier and contribute to maintaining the 
intestinal barrier function. Intestinal permeability is the 
measure of this function and it is mainly the sum of 
paracellular permeability making tight junctions vital for 
upholding the intestinal barrier. Tight junctions are 
dynamic protein complexes that are constantly assembled, 
modified, and maintained when epithelial cells proliferate 
to form the intact epithelium.   
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2.2 Factors that affect intestinal permeability 
2.2.1 Intestinal inflammation 
Pro-inflammatory cytokines, such  as tumor necrosis factor (TNF)-α and 
interferon (IFN)-γ, disrupt the intestinal barrier with numerous studies 
detailing their effects of intestinal permeability (for review, see Suzuki, 2013). 
The current evidence suggests that, although increased enterocyte apoptosis 
and cell shedding may also play a role (Watson and Hughes, 2012), pro-
inflammatory cytokines increase intestinal permeability primarily via 
mechanisms involving tight junctional modifications (Suzuki, 2013; Turner, 
2009). These modifications include MLCK-mediated changes in tight junctional 
structure and alterations in the expression of tight junctional proteins (Al-Sadi 
et al., 2014, 2012, 2011b, Bruewer et al., 2005, 2003, Clayburgh et al., 2006, 2005; 
Marchiando et al., 2010b; Yang et al., 2013; Ye et al., 2006). 
Clinically, inflammatory mediators likely contribute to barrier defects observed 
in several pathological conditions but the interplay between them and intestinal 
permeability is especially interesting for the development of IBD. IBDs, such as 
Crohn’s disease (CD) and ulcerative colitis (UC), are characterized as chronic 
inflammation of the intestine which leads to ulceration, intestinal bleeding, and 
diarrhea. The treatment of IBD relies on alleviating the underlying intestinal 
inflammation with immunosuppressive medication such as corticosteroids, 
anti-TNF-α agents and other biologic inhibitors. The main features of CD and 
UC include increased intestinal permeability and increased mucosal levels of 
pro-inflammatory cytokines but the causality of this association remains 
uncertain (Michielan and D’Incà, 2015). On one hand, a subset of healthy first-
degree relatives of CD patients exhibit increased intestinal permeability 
(Buhner et al., 2006; D’Incà et al., 2006; Fries et al., 2005) and at least in one 
case study increased intestinal permeability at the age of 13 preceded the onset 
of CD later in life (Irvine and Marshall, 2000). Increased intestinal permeability 
seems to also predict disease relapse in patients with inactive CD (Arnott et al., 
2000; D’Incà et al., 1999). Furthermore, animal models of IBD, such as IL-10-/- 
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and Samp/YitFc mice which spontaneously develop colitis and ileal 
inflammation, respectively, show increased intestinal permeability before the 
development of intestinal inflammation (Madsen et al., 1999; Olson et al., 
2006). In IL-10-/- mice, modulating intestinal permeability also affects the 
severity of the disease (Arrieta et al., 2015, 2009). These findings would suggest 
that defects in intestinal barrier function drive the pathogenesis of IBD.  
On the other hand, anti-TNF-α antibody infliximab restores CD patients’ 
intestinal permeability to the level of healthy controls (Noth et al., 2012; 
Suenaert et al., 2002) citing inflammation as the cause of increased intestinal 
permeability in these patients. Also, studies on different animal models have 
revealed that increased intestinal permeability alone does not always lead to 
overt intestinal inflammation. For example, JAM-A-/- mice (Khounlotham et al., 
2012), claudin-2 overexpressing mice (Ahmad et al., 2014), and mice expressing 
constitutively active MLCK (Su et al., 2009) all show increased intestinal 
permeability but do not develop colitis spontaneously. These models suggest 
that additional triggers besides increased intestinal permeability are needed for 
the development of IBD. Hence, the primary barrier defect in IBD likely results 
from abnormal mucosal immune response leading to subclinical inflammation 
which subsequently exacerbates the existing condition. This vicious cycle 
eventually leads to extensive intestinal inflammation and to the development 
of the disease. Most likely though, the interplay between inflammation and 
intestinal permeability involves also other factors (genetic, environmental, 
microbial) that impact the intestinal barrier and contribute to disease 
pathogenesis in IBD. 
2.2.2 Intestinal microbes 
Commensal microbes residing in the intestine regulate the intestinal barrier 
function via several mechanisms (Yu et al., 2012). Firstly, by inhabiting the 
intestinal lumen, commensal bacteria prevent the colonization of pathogenic 
bacteria. A good example of the protective impact of commensal microbiota is 
the possible expansion of pathogenic Clostridium difficile in the intestinal 
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lumen and subsequent diarrhea following the use of antibiotics (Deshpande et 
al., 2013). Secondly, intestinal microbiota metabolizes some of the undigested 
carbohydrates to short-chain fatty acids (SCFAs), such as butyrate. Butyrate is 
a major energy source for colonocytes and it has shown various beneficial effects 
for intestinal barrier function (for review, see Plöger et al., 2012). Interestingly, 
studies have reported decreased abundances of butyrate-producing bacteria in 
CD (Takahashi et al., 2016), UC (Machiels et al., 2014), IBS (Pozuelo et al., 2015), 
and type-1-diabetes (Vaarala, 2013), which are all conditions associated with 
increased intestinal permeability.  
Thirdly, the direct interactions between commensal bacteria and the host are 
critical for maintaining the intestinal homeostasis. The intestinal epithelium 
contains different patter-recognition receptors (PRRs) which recognize and 
respond to bacterial components, such as lipopolysaccharide (LPS), 
peptidoglycans, and flagellins (Martini et al., 2017). When these components 
bind to PRRs, they elicit the secretion of antimicrobial peptides, different 
cytokines, and other substances which modulate the immunological response 
and also shape the composition of intestinal microbiota (Fukata and Arditi, 
2013). This immunomodulatory system has several implications for intestinal 
barrier function. For example, under germ-free conditions, colitis-prone IL-10-
/- mice do not develop permeability defects nor colitis indicating that abnormal 
immune response to intestinal microbes prompts the disease (Madsen et al., 
1999). In humans, one of the major susceptibility loci for CD development is the 
gene for PRR called nucleotide-binding oligomerization domain-containing 
protein (NOD)-2 (Hugot et al., 2001) and a few studies have associated NOD2 
gene variants with increased intestinal permeability in healthy relatives of CD 
patients (Buhner et al., 2006; D’Incà et al., 2006). Furthermore, NOD2-/- mice 
exhibit increased intestinal permeability suggesting its role in maintaining 
intestinal barrier function (Al Nabhani et al., 2016). Another important PRR 
group in the context of intestinal permeability are toll-like receptors (TLRs). 
TLR signaling in the intestine forms a complex network with different receptors 
exerting pro-inflammatory and anti-inflammatory effects depending on the 
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receptor subtype and location (Fukata and Arditi, 2013). In mice, the deletion of 
TLR4 gene, a major receptor for bacterial LPS, prevents LPS-induced increase 
in intestinal permeability (Guo et al., 2015). On the other hand, TLR2 agonist 
ameliorates chemically-induced colitis in mice by restoring the intestinal 
barrier function (Cario et al., 2007). 
Considering the interplay between PRRs and intestinal microbiota, abnormal 
PRR function likely contributes to intestinal dysbiosis. Intestinal dysbiosis is a 
frequently used, but loosely defined, term for reduced richness and diversity of 
intestinal microbiota and it is often considered as a sign of intestinal 
inflammation (Suchodolski, 2016). However, whether intestinal dysbiosis itself 
increases intestinal permeability remains uncertain. NOD2-/- mice show 
increased intestinal permeability and intestinal dysbiosis but these two events 
seem to occur independently as NOD2-/- associated-microbiota in wild-type 
control does not increase intestinal permeability (Al Nabhani et al., 2016). In 
contrast, studies in fruit flies have revealed that intestinal dysbiosis precedes 
intestinal barrier defect and this defect further exacerbates the dysbiosis (Clark 
et al., 2015). Similarly, a recent study in mice showed that microbial dysbiosis 
can increase intestinal permeability and the subsequent inflammation further 
contributes to the dysbiosis (Thevaranjan et al., 2017). 
2.2.3 Dietary factors 
The human diet contains several nutrients and molecules which can impact 
intestinal barrier function. In recent years, the relationship between intestinal 
permeability, obesity, and Western diet (a diet containing high amounts of fat 
and sugar) has been under extensive research. The current hypothesis states 
that increased intestinal permeability contributes to the pathophysiology of 
obesity-related diseases by allowing the translocation of LPS into circulation. 
This leads to a condition labeled metabolic endotoxemia which triggers the low-
grade inflammation associated with obesity and obesity-related disorders. 
Multiple recent animal studies have reported increased intestinal permeability 
following a high-fat or high-fat/high-sugar diet (Cani et al., 2008; Hamilton et 
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al., 2015; Johnson et al., 2015; Martinez-Medina et al., 2014; Murakami et al., 2016; 
Serino et al., 2012; Stenman et al., 2012; Volynets et al., 2017) but whether this 
effect is caused by the diet or by diet-induced obesity remains uncertain. 
Studies on this have produced mixed findings with some reporting that 
genetically obese rodents exhibit increased intestinal permeability (Brun et al., 
2007; Johnson et al., 2015) whereas others have reported normal permeability 
measures in these animals (Stenman et al., 2013b; Suzuki and Hara, 2010). 
Nonetheless, these findings are clinically relevant because they have linked 
increased intestinal permeability to the pathogenesis of obesity-related 
metabolic disorders, such as type-2-diabetes (T2D), nonalcoholic fatty liver 
disease (NAFLD), and nonalcoholic steatohepatitis (NASH). Indeed, obese 
people and patients with these diseases seem to be more likely to have increased 
intestinal permeability compared to healthy controls (Horton et al., 2014; Leber 
et al., 2012; Luther et al., 2015; Teixeira et al., 2012b).  
Investigations into the mechanisms behind increased intestinal permeability in 
diet-induced obesity have revealed two major players: intestinal microbiota and 
bile acids. Regarding microbiota, Serino et al. (2012) showed that 
supplementing high-fat diet with gluco-oligosaccharide, a microbiota-
modifying prebiotic, stunts both the increase in intestinal permeability and in 
blood LPS levels. Antibiotics have a similar effect (Cani et al., 2008) which 
further suggests that changes in microbiota contribute the diet-induced barrier 
defect. Another possible mechanism relates to bile acids. Bile acids facilitate the 
absorption of fatty acids from the intestine and their secretion is increased in 
response to high-fat diet. Stenman et al. (2012) reported that mice fed with high-
fat diet exhibit altered fecal bile acid profile and this relates to increased 
intestinal permeability. Later, they showed that fecal concentrations of 
hydrophobic bile acid, deoxycholic acid (DCA), associated with high-fat feeding 
are able to disrupt the intestinal barrier (Stenman et al., 2013a). Considering 
that multiple studies have shown the barrier-disrupting effects of DCA 
(Chadwick et al., 1979; Fihn et al., 2000; Goerg et al., 1983; Hughes et al., 2008; 
Münch et al., 2007; Sun et al., 2004), it is likely that bile acids also contribute to 
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the observed increase in intestinal permeability during high-fat diet. However, 
it should be kept in mind that intestinal microbiota affects the composition of 
the bile acid pool and vice versa so it is highly probable that changes in one 
during high-fat diet also elicit changes in the other (Ridlon et al., 2014). Thus, 
more studies are needed on their synergistic effects in controlling intestinal 
barrier function during high-fat feeding. 
Another disease associated with increased intestinal permeability and dietary 
habits is alcoholic liver disease (ALD). The etiology of ALD seems similar to that 
of NAFLD in that increased intestinal permeability permits the increased 
translocation of LPS into circulation and liver. Studies have shown that chronic 
and acute ethanol consumption increase intestinal permeability (Leclercq et al., 
2017) and that changes in intestinal permeability may precede the onset of liver 
disease (Keshavarzian et al., 2009). Interestingly, alcoholics with chronic liver 
disease exhibit higher intestinal permeability than alcoholics with no liver 
disease suggesting that intestinal permeability plays a role in the development 
of ALD (Keshavarzian et al., 1999). The mechanisms by which ethanol disrupts 
the intestinal barrier involve oxidative stress and tight junctional modifications 
(Leclercq et al., 2017). In addition, the intestinal microbiota plays a role in 
ethanol-induced barrier defect as germ-free mice do not show increased 
intestinal permeability after acute alcohol consumption (Canesso et al., 2014). 
Recently, Leclerq et al. (2014) identified two subsets of alcoholics: those with 
increased intestinal permeability and those whose intestinal permeability was 
comparable to healthy controls. Intriguingly, intestinal dysbiosis was only 
present in the alcoholics with increased intestinal permeability and they also 
suffered greater levels of psychological symptoms during alcohol withdrawal 
(Leclercq et al., 2014). Also, when germ-free mice are inoculated with 
microbiota from an alcohol-dependent subject with severe liver disease, they 
exhibit greater intestinal permeability and liver damage after alcohol-feeding 
than comparable mice harboring microbiota from a similar subject without liver 
disease (Llopis et al., 2016). These results suggest that ethanol and gut 
microbiota act synergistically in the intestine to disrupt the barrier-function.  
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Of individual nutrients that affect intestinal permeability, gliadin, a component 
of grain protein gluten, has received a lot of attention due to its role in the 
pathogenesis of celiac disease. Gliadin increases intestinal permeability by 
inducing the secretion of zonulin (Lammers et al., 2008) (see, p. 39) and this 
response is greater in celiac patients (Drago et al., 2006). Increased intestinal 
permeability also seems to affect the development of food allergies (Järvinen et 
al., 2013; Ventura et al., 2006). Certain amino acids, such as glutamine, arginine, 
and tryptophan, have also shown barrier-enhancing properties when 
administered to different animal models (Andrade et al., 2015). In addition, 
vitamin D supplementation maintains intestinal permeability measures at 
remission level in CD patients (Raftery et al., 2015) possibly by suppressing 
MLCK-mediated tight junctional modifications (Du et al., 2015). 
2.2.4 Psychological and physical stress 
Acute and chronic psychological stress cause various physiological, metabolic, 
and behavioral alterations but also modulate the properties of the intestinal 
barrier. Different animal models of stress exhibit increased intestinal 
permeability and convergent evidence suggests that the primary mechanism 
behind this event involves corticotropin-releasing factor (CRF) signaling (Kelly 
et al., 2015; Rodiño-Janeiro et al., 2015). Hypothalamic CRF secretion is one of 
principal mediators of the systemic stress response and this central release of 
CRF also acts in the intestine by activating enteric CRF-receptors. Intestinal 
immune cells and enterochromaffin cells also produce CRF locally in the 
intestine (Rodiño-Janeiro et al., 2015). In the context of intestinal permeability, 
in vivo and ex vivo studies have shown that stress and exogenous CRF 
administration increase intestinal permeability via activation of intestinal mast 
cells and that pharmacological mast cell inhibitors block this effect (Lennon et 
al., 2013; Overman et al., 2012; Smith et al., 2010; Vanuytsel et al., 2014). 
Clinically, psychological stress has been associated with the development of 
IBD, IBS, and other gastrointestinal disorders (Brzozowski et al., 2016) which 
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highlights the role of gut-brain axis and the enteric nervous system in the 
maintenance of the intestinal barrier.  
In addition to psychological stress, physical stressors, such as trauma and high-
intensity exercise, have been shown to increase intestinal permeability. 
Although the mechanisms by which they compromise the intestinal barrier 
likely overlap (Clark and Mach, 2016; Hill et al., 2013), the main mechanism 
behind barrier defects during or after physical stress is gastrointestinal 
hypoperfusion and ischemia. Ischemia and the subsequent restoration of blood 
flow induce enterocyte damage, oxidative stress, and inflammation which 
compromise the integrity of the epithelium (van Wijck et al., 2012a). In trauma 
patients, intestinal cell damage is thought to facilitate bacterial translocation 
and sepsis which ultimately lead to multi-organ failure, a common cause of 
death in intensive care (Bischoff et al., 2014; Swank and Deitch, 1996). Regarding 
exercise, athletes frequently suffer from various gastrointestinal symptoms 
during training (Oliveira et al., 2014) and intestinal hypoperfusion is 
acknowledged as the leading cause behind these disorders (ter Steege et al., 
2012; ter Steege and Kolkman, 2012). However, although several studies have 
reported increased intestinal permeability following high-intensity exercise 
(Davison et al., 2016; March et al., 2017; Marchbank et al., 2011; Oktedalen et al., 
1992; Pals et al., 1997; van Nieuwenhoven et al., 2004; van Wijck et al., 2011; Zuhl 
et al., 2015), it remains unclear whether compromised barrier function 
contributes to gastrointestinal symptoms during exercise. Previously, van 
Nieuwenhoven et al. (2004) reported that symptomatic athletes exhibit higher 
intestinal permeability after exercise than asymptomatic athletes, but this 
comparison was based on historical asymptomatic controls who used a different 
mode of exercise. It is also unclear whether exercise-induced increase in 
intestinal permeability leads to elevated levels of LPS in circulation or if LPS 
mediates symptom development during exercise. Studies have reported 
increased blood concentrations of LPS following exercise (Ashton et al., 2003; 
Bosenberg et al., 1988; Gill et al., 2015; Jeukendrup et al., 2000; Lim et al., 2009; 
Moncada-Jimènez et al., 2009; Yeh et al., 2013) but aside from a single study 
REVIEW OF LITERATURE 
 30
(Brock-Utne et al., 1988) it does not appear to directly correlate with the 
occurrence of gastrointestinal symptoms. These observations suggest that 
although increased intestinal permeability may play a role in exercise-induced 
gastrointestinal symptoms, more research is needed to elucidate the 
pathophysiological mechanisms that lead to symptoms in individual athletes.     
2.2.5 Chemotherapy   
Gastrointestinal toxicity is the most common adverse event associated with 
chemotherapeutic drugs (Andreyev et al., 2012). Chemotherapeutics are 
cytotoxic agents designed to kill rapidly dividing cells by inhibiting DNA 
replication with various mechanisms and thus interfering with cell division. For 
example, antimetabolites 5-FU and methotrexate disrupt the production of 
nucleotide thymidine needed for DNA synthesis. Platinum-based 
chemotherapeutics, such as cisplatin and oxaliplatin block DNA replication by 
forming adducts with the DNA strands. In contrast, irinotecan inhibits DNA 
topoisomerase-1, an enzyme needed during DNA replication. Regardless of the 
mechanism, chemotherapeutics disrupt the natural turnover of enterocytes and 
thus impact the intestinal mucosa. However, the pathophysiology of 
chemotherapy-induced gastrointestinal toxicity (CIGT) seems to be much more 
complicated and extend beyond simple cellular damage. Previously, Sonis 
(2004) proposed five overlapping phases for the development of CIGT. First, 
chemotherapeutics disrupt the cells’ DNA resulting to cellular damage and to 
the generation of reactive oxygen species (Initiation phase). This initial damage 
activates transcription factors, such as nuclear factor-κB, leading to the release 
of pro-inflammatory cytokines that further exacerbate the initial injury 
(Primary damage response phase). The release of pro-inflammatory cytokines 
creates a positive-feedback loop that further amplifies the damage (Signal 
amplification phase) eventually compromising the integrity of the intestinal 
barrier (Ulceration phase). Finally, when the chemotherapy is stopped, mucosal 
cells start to proliferate and the tissue heals (Healing phase) (Sonis, 2004). 
Recent evidence has expanded this model by introducing the effects of 
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intestinal microbiota to pathophysiology of CIGT (Alexander et al., 2017; van 
Vliet et al., 2010). 
Indeed, multiple animal and clinical studies have reported increased intestinal 
permeability following the administration of different chemotherapeutics and 
chemotherapy-regimens (Beutheu et al., 2014; Choi et al., 2007; Daniele et al., 
2001; Fazeny-Dörner et al., 2002; Generoso et al., 2015; Justino et al., 2014; Kato 
et al., 2017; Keefe et al., 1997; Lima-Júnior et al., 2014; Melichar et al., 2008, 2007; 
Russo et al., 2013; Vanhoecke et al., 2015; Wang et al., 2015; Wardill et al., 2016). 
The exact molecular mechanisms by which individual chemotherapeutics 
disrupt the intestinal barrier remain poorly defined. Overall, the molecular 
mechanisms of the pathophysiology of CIGT likely involve tight junctional 
modifications (Wardill and Bowen, 2013), inflammatory cascades (Cario, 2016; 
Lee et al., 2014), and gut microbiota modulations (Touchefeu et al., 2014). The 
molecular mechanisms behind these events are best characterized with 
irinotecan while studies with other chemotherapeutics mainly describe 
increased inflammatory activity following chemotherapy. The pathophysiology 
of irinotecan-induced gastrointestinal toxicity has also been under interest due 
to irinotecan’s unique metabolism by the intestinal microbiota (Alexander et 
al., 2017). Some bacterial species express an enzyme called β-glucuronidase that 
can metabolize irinotecan inactive, glucuronidated metabolite back to its active 
form and thus increase its toxicity. Recently, Pedroso et al. (2015) showed that 
germ-free mice mono-colonized with a bacterial strain that does not produce 
β-glucuronidase exhibit irinotecan-induced intestinal toxicity but not increased 
intestinal permeability. Also, considering that inhibiting this enzyme alleviates 
irinotecan-induced diarrhea (Wallace et al., 2010) and the efficacy of antibiotics 
(Bowen et al., 2007; Kurita et al., 2011) as well as pro- and prebiotics (Bowen et 
al., 2007; Lin et al., 2014) in reducing irinotecan’s toxicity, the intestinal 
microbiota seems to be a vital at least for the pathophysiology of irinotecan-
induced gastrointestinal toxicity. 
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To summarize, several factors impact the integrity of the 
intestinal barrier. Of special importance is the interplay 
between intestinal permeability, intestinal microbes, and 
inflammatory signals. It seems that factors capable of 
affecting this balance by either directly damaging the 
intestinal epithelium, modulating intestinal microbiota, or 
inducing inflammatory processes disrupt the intestinal 
homeostasis which starts a self-propagating cycle that 
results in more widespread changes and possibly disease. 
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2.3 How to measure intestinal permeability? 
2.3.1 Direct permeability assays in vitro 
Permeability assays in vitro are based on human colon tumorigenic cell lines 
which upon differentiation form enterocyte-like, polarized monolayers that 
resemble the intestinal epithelium (Cencic and Langerholc, 2010; Volpe, 2010). 
The most commonly used cell lines in these assays are Caco-2, HT-29, and T84 
(Cencic and Langerholc, 2010). In permeability studies, these cells are cultivated 
on a semi-porous membrane separating the apical (luminal) and basolateral 
(submucosal) compartments. The macromolecular permeability of the 
monolayer can be assessed by introducing a probe molecule to the apical 
compartment and measuring the rate at which it translocates to the basolateral 
compartment. Frequently used probes in these assays are different sized 
fluorescein isothiocyanate (FITC)-labeled dextran and polyethylene glycol 
(PEG) polymers, fluorescein, Evans blue, and lucifer yellow due to their simple 
detection with a fluorescence counter. In addition to permeability probes, in 
vitro studies often use the TER value of the cell monolayer as a measure of its 
integrity. 
2.3.2 The Ussing chamber for ex vivo permeability assays 
Developed by a Danish biologist Hans Ussing in 1951 (Ussing and Zerahn, 1951), 
the Ussing chamber is still a widely used ex vivo approach for studying epithelial 
permeability (Clarke, 2009). A permeability assay in the Ussing chamber system 
requires a freshly harvested intestinal tissue segment that is mounted between 
two chamber halves separating the luminal and submucosal sides.  To ensure 
the viability of tissue segment, each chamber half is filled with equal amounts 
of physiological buffer solution with continuous oxygenation and the whole 
system is water-jacketed to mimic mammalian body temperatures. Each 
chamber also contains two pairs of electrodes. The first set of electrodes 
measures the spontaneously developing voltage difference (Vt) across the tissue 
segment while the other electrode pair generates a current that nulls this 
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difference. This current is called the short-circuit current (Isc) and it 
corresponds to the sum of all active ion movement across the epithelium. For 
an excellent review of the Ussing chamber set-up, see Clarke (2009). 
Regarding permeability measurements in the Ussing chamber, the integrity of 
the paracellular pathway can be estimated from the TER values of the tissue 
segments. The TER values can be derived from the Isc and Vt values according 
to the Ohm’s law: 
ܴ ൌ ܸ ܫΤ  
where the R is the resistance of the conductor in ohms (i.e. TER), the V is the 
voltage across the conductor in volts (i.e. the voltage difference between the 
two chambers), and the I is the current through the conductor in amperes (i.e. 
the Isc). However, considering that the TER value mostly relates to paracellular 
ionic conductance regulated by the pore pathway (see Chapter 2.1.2., p. 16), 
changes in TER alone may not reflect changes in macromolecular permeability. 
In the Ussing chamber, macromolecular permeability can be assessed similarly 
as in in vitro studies by measuring the appearance of a permeability probe to 
the submucosal chamber from the apical side. The probes used in these studies 
are also similar to those used in vitro studies. However, the major advantage of 
the ex vivo approach compared to the cell models is that the tissue segment 
retains the natural cellular diversity and complexity of the intestine. The 
limitations of the Ussing chamber are its invasiveness due to the requirement 
for intestinal tissue and the relatively short viability of intestinal tissue 
segments outside the body which limits measurement times. In addition, 
depending on the preparation of the tissue segment prior to mounting to the 
Ussing chamber, the intestinal specimen may include other anatomical 
structures besides to the epithelium which can form permeability barriers.  
2.3.3 Direct permeability assays in vivo 
In vivo measurements of intestinal permeability attempt to assess changes in 
intestinal barrier function on a systemic level. These assays are based on the 
oral administration of specific probe molecules and their subsequent analysis 
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from blood or urine. Most assays employ urine collection times ranging from 5-
24 h with blood samples usually taken 1-2 hours after probe ingestion. Increased 
blood or urine concentrations of the probe indicate increased intestinal 
permeability suggesting impaired barrier function. This methodology poses 
several requirements for the probe molecules (for review, see Bjarnason et al., 
1995). In general, they should be water-soluble, non-toxic, not actively absorbed 
from the intestine, not naturally present in the host, not metabolized, and easily 
detectable. A suitable probe for an individual study also depends on which 
segment of the gastrointestinal tract is under investigation (Arrieta et al., 2006). 
The most frequently used probes for in vivo intestinal permeability 
measurements are small sugar molecules and disaccharides. Usually, the 
measurement is done by combining a small molecule (e.g. mannitol or 
rhamnose) with a disaccharide (e.g. lactulose) and intestinal permeability is 
expressed as the ratio between the two probes. The idea is that the smaller 
molecule acts as an internal standard eliminating individual differences in 
gastrointestinal motility and renal clearance. Currently, the lactulose/mannitol 
(L/M)-ratio is considered the golden standard for intestinal permeability 
measurements.  
A unique feature in using sugar molecules as permeability probes is that they 
are susceptible to degradation in the intestine. For instance, colonic bacteria 
degrade both mannitol and lactulose meaning that their permeability reflects 
small intestinal permeability (Arrieta et al., 2006). On the other hand, sucrose 
is already metabolized in the duodenum making it a suitable probe for 
gastroduodenal permeability (Meddings et al., 1993). Whole gastrointestinal 
permeability can be assessed with sucralose or erythritol which are not 
degraded at any part of gastrointestinal tract. When sucralose is used together 
with lactulose, colonic permeability can be calculated by subtracting urinary 
lactulose excretion from urinary sucralose excretion (Bischoff et al., 2014). 
Furthermore, the individual differences between the degradation patterns of 
different sugar probes enables the use of several sugar probes in a single 
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measurement and assess gastroduodenal, small intestinal, and colonic 
permeability simultaneously (van Wijck et al., 2013). However, the use of sugar 
probes also possesses several limitations (for review, see Salles Teixeira et al., 
2014). Small intestinal bacterial overgrowth or intestinal dysbiosis may impact 
measurements using sugars susceptible to bacterial degradation. Lactulose, 
mannitol, and sucralose are also present in multiple food products which 
requires careful monitoring of diet during the measurement period (Salles 
Teixeira et al., 2014). The analysis of sugars also requires complex detection 
methods, such as high-pressure liquid chromatography (HPLC) or liquid 
chromatography combined with mass spectrometry (LC/MS), which are not 
widely available. 
Other suitable probes for in vivo permeability measurements include PEG 
polymers, 51Cr-labeled ethylenediaminetetraacetic acid (51Cr-EDTA), and 
iohexol (Salles Teixeira et al., 2014). All these probes pass through the intestinal 
tract non-metabolized and thus can be used for whole gut permeability assays. 
Similarly to sugar probes, PEG polymers require laborious detection methods 
(HPLC or LC/MS) and currently, they are not widely used in permeability 
studies. In contrast, the main advantage of using 51Cr-EDTA is the radioactive 
label that makes its detection simple (Bjarnason et al., 1995). However, its 
radioactivity also makes it unsuitable for certain patients and may raise 
concerns about safety and proper handling of the probe. The use of 
radioisotopes can also be expensive and requires a permit which can further 
limit the use of 51Cr-EDTA. Iohexol is a routinely used as a contrast medium in 
X-ray based imaging techniques but studies have shown that it is also suitable 
for intestinal permeability measurements (Andersen et al., 2001; Frias et al., 
2014; Gerova et al., 2011; Halme et al., 2000, 1997, 1993). Compared to sugar 
probes, it is not affected by the intestinal microbiota and its detection can be 
done with a commercially available enzyme-linked immunosorbent assay 
(ELISA) kit. It is also non-radioactive, cheap, and due to its widespread use in 
clinical imaging it is readily available in clinical settings. However, studies using 
iohexol as a permeability marker are still rare and more studies are needed to 
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validate the method. Iohexol also contains iodine which prohibits its use in 
patients sensitive to iodine.    
So far, intestinal permeability assays have not reached widespread use in clinical 
practice and they are mainly employed only for scientific investigations 
(Bischoff et al., 2014). This could be due heterogeneity in methodology between 
studies which has led to a lack of understanding of what constitutes as normal 
intestinal permeability in a certain situation. Also, direct permeability assays 
with urine collections times of 5-24 hours and laborious detection methods 
might be impractical to use in everyday clinical practice. Different probe 
molecules and their features are listed in Table 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
 38
Table 1. Frequently used probe molecules in direct permeability measurements 
(modified from Vancamelbeke and Vermeire, 2017). 
Permeability probes Use in permeability assays 
Sugar molecules    
Mannitol 
Rhamnose 
In vivo, used together with lactulose to measure 
small intestinal permeability, bacterial degradation, 
laborious detection 
Sucrose In vivo, degraded in the duodenum, reflects 
gastroduodenal permeability, laborious detection 
Lactulose In vivo, used to measure small intestinal 
permeability, bacterial degradation, laborious 
detection  
Sucralose In vivo, whole intestinal permeability 
measurements, laborious detection 
Radioactive    
51Cr-EDTA In vivo, whole intestinal permeability 
measurements, radioactivity a major disadvantage 
Contrast medium    
Iohexol In vivo, whole intestinal permeability 
measurements 
Polymers    
Polyethylene glycols In vivo, whole intestinal permeability 
measurements, laborious detection 
Fluorescent    
Fluorescein 
Evans blue 
Lucifer yellow 
In vitro and ex vivo permeability assays, easy 
detection 
FITC-labeled 
dextrans 
In vitro and ex vivo permeability assays, used also 
in vivo in rodents, easy detection 
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2.3.4 Indirect measures of intestinal barrier function 
Studies have also employed several indirect markers to assess the integrity of 
intestinal epithelium. Although these markers might not directly represent 
increased macromolecular flux from the intestinal lumen into circulation, they 
could provide valuable information about gastrointestinal function and health.  
Zonulin is the only known physiological modulator that specifically targets tight 
junctions and elevated blood levels of zonulin are considered as a sign of 
increased intestinal permeability. Indeed, increased concentrations of zonulin 
have been associated with the development of several diseases also associated 
with increased intestinal permeability (for review, see Sturgeon and Fasano, 
2016). So far, studies have identified two major triggers for zonulin release: 
intestinal bacteria and gliadin. Gliadin-stimulated zonulin release is thought to 
contribute to pathophysiology of celiac disease because intestinal tissue 
samples from patients with celiac disease exhibit higher zonulin release and 
increased intestinal permeability following gliadin treatment (Drago et al., 
2006). Another disease associated with elevated zonulin levels is T1D. In T1D 
patients and their relatives, increased zonulin concentrations correlated with in 
vivo permeability (Sapone et al., 2006) and in a diabetes-prone rat model 
zonulin blocker administration decreased intestinal permeability and diabetes 
incidence (Watts et al., 2005). In addition to T1D, elevated zonulin levels have 
been associated with obesity (Moreno-Navarrete et al., 2012; Zak-Gołąb et al., 
2013) and obesity-related disorders, such as T2D (Zhang et al., 2014) and NAFLD 
(Pacifico et al., 2014). Recently, Mokkala et al. (2016) studied zonulin levels in 
overweight pregnant women and reported that increased zonulin levels 
associate with decreased richness of intestinal microbiota (Mokkala et al., 2016), 
circulating levels of LPS and inflammatory markers (Mokkala et al., 2017a), and 
increased risk of gestational diabetes (Mokkala et al., 2017b). However, more 
research is needed to elucidate the role of zonulin in the normal regulation of 
the intestinal barrier. 
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Increased levels of LPS are often interpreted to reflect increased intestinal 
permeability. However, other factors also contribute to circulating LPS 
concentrations (Teixeira et al., 2012a). For example, changes in the composition 
of intestinal microbiota may lead to elevated LPS production in the intestinal 
lumen and thus raise blood LPS levels without any changes in intestinal barrier 
function. Also, several physiological mechanisms clear LPS from circulation so 
individual differences in these mechanisms affect blood LPS concentrations. 
Studies have also shown that LPS can cross the intestinal epithelium 
transcellularly via chylomicron-mediated mechanisms. Thus, although 
circulation LPS levels may be a good indicator of the consequences of barrier 
defects, they should not be considered as a direct measure of intestinal 
permeability. 
Fatty acid-binding proteins (FABPs) are proteins present in the apical 
membrane of mature enterocytes. The intestinal tract expresses three types of 
FABP: liver-type FABP (L-FABP), intestinal-type FABP (I-FABP), and ileal bile 
acid-binding protein (I-BABP) (Bischoff et al., 2014). Upon enterocyte damage, 
FABPs are released into circulation and increased blood concentrations of 
FABPs have been observed following abdominal tissue injury (Relja et al., 2010) 
and intestinal ischemia during exercise (ter Steege et al., 2012; van Wijck et al., 
2011). Serum I-FABP levels also associate with the severity of villous atrophy in 
celiac disease (Adriaanse et al., 2013). Another marker of enterocyte function is 
citrulline. Citrulline is produced in enterocytes from glutamine and decreased 
levels of citrulline in blood reflect the loss of enterocyte mass. Citrulline has 
shown promise as a biomarker for chemotherapy-induced gastrointestinal 
mucositis (van Vliet et al., 2009). 
Urinary excretion of tight junction protein claudin-3 has also been used to 
assess intestinal barrier function. Studies have reported elevated levels of 
claudin-3 after exercise (Yeh et al., 2013), in IBD patients (Thuijls et al., 2010a), 
and in necrotizing enterocolitis (Thuijls et al., 2010b). 
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Calprotectin is a frequently used fecal biomarker of intestinal inflammation. In 
clinical practice, fecal calprotectin is used to differentiate between IBDs and 
other functional gastrointestinal disorders, such as IBS (Sipponen and Kolho, 
2015). Fecal calprotectin measurements are also used to monitor the disease 
activity in IBD (Sipponen and Kolho, 2015). However, as barrier defects may 
arise also independent of inflammation, fecal calprotectin should only be 
considered as a measure of intestinal inflammation. 
To summarize, the basic concept of direct intestinal 
permeability assay is to measure the translocation of a 
probe molecule across the intestinal epithelium. This can 
be done in vitro using certain cell lines, ex vivo by 
harvesting tissue samples or biopsies or in vivo with probes 
that can be detected from blood or urine. Indirect 
biomarkers are also useful for assessing the health of the 
intestinal barrier but should not be taken as a measure of 
intestinal permeability.   
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3 AIMS OF THE STUDY 
Increased intestinal permeability is a common feature in multiple pathologies. 
This thesis consists of two animal studies and a clinical study with each study 
focusing on different stressor impacting intestinal permeability. The first 
animal study (Studies I/II) investigated the association between intestinal 
permeability and chemotherapy-induced gastrointestinal toxicity. The second 
animal study was an ex vivo study examining the mechanism by which 
hydrophobic bile acid deoxycholic acid (DCA) affects intestinal permeability 
(Study IV). In the clinical study, we examined how intestinal permeability 
relates to gastrointestinal symptoms during exercise (Study III). 
The specific aims were: 
 
I. To study how individual chemotherapeutics affect intestinal 
permeability and whether intestinal permeability to iohexol 
correlates with the severity of chemotherapy-induced 
gastrointestinal toxicity (CIGT). (Study I) 
II. To test the hypothesis that CIGT is associated with changes in 
fecal microbiota, and the metabolome of serum and urine. (Study 
II) 
III. To examine how chemotherapy-induced changes in the 
composition of fecal microbiota and the metabolome relate to 
CIGT and increased intestinal permeability. (Study II) 
IV. To analyze running-induced changes in intestinal permeability 
and other markers of gastrointestinal function and study their 
possible associations with gastrointestinal symptoms during 
running. (Study III) 
V. To elucidate the mechanisms by which DCA increases intestinal 
permeability. (Study IV) 
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4 MATERIALS AND METHODS 
4.1 Experimental animals and study subjects 
4.1.1 Experimental animals 
For Study I/II, a total of 48 male Sprague–Dawley rats were obtained from 
Harlan (Udine, Italy) at the age of six weeks. The animals were acclimatized for 
18 days before the commencement of experimental protocol. The animal 
experiment was approved by the National Animal Experiment Board 
(ESAVI/114/04.10.07/2015). 
A total of 20 male c57Bl/6JOlaHsd mice (Harlan, UK) between the age of eight 
and ten weeks were included in Study IV. The animal experiment was approved 
by the National Animal Experiment Board (ESAVI/6806/04.10.03/2011). 
All animals were housed in a specific pathogen-free rodent facility with a 12-h 
light/dark cycle in a room temperature of 22 ± 2°C and relative humidity of 55 
± 15%. All experimental animals had free access to food (2018 Teklad Global 18% 
Protein Rodent Diet, Harlan Laboratories, Madison, WI, USA) and tap water. 
4.1.2 Study subjects 
For Study III, a total of 24 active runners were recruited via online recruitment 
posters. All suitable study subjects were asked to sign a written consent form to 
confirm their participation to the study. After drop-outs, the group of subjects 
completing the whole study protocol consisted of 9 males and 8 females 
between the age of 24 and 44. Exclusion criteria included gastrointestinal 
illness, asthma, heart or cardiovascular diseases, pregnancy, breast-feeding, and 
iodine allergy. The study was conducted in adherence to the ethical regulations 
outlined in the Declaration of Helsinki and the study was approved by the 
Hospital District of Helsinki and Uusimaa (HUS) Coordinating ethics 
committee (13/13/03/00/2015). 
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4.2 Study designs 
4.2.1 Study I/II 
Following the 18-day acclimatization period, the rats were randomized into four 
experimental groups: Control, 5-fluorouracil (5-FU), Oxaliplatin, and 
Irinotecan. Baseline samples of serum, urine, and feces were collected and a 
baseline measurement of in vivo intestinal permeability to iohexol was 
performed before any drug injections.  
After baseline sample collection, the animals could recuperate for 13 days after 
which they    received a single intraperitoneal injection of either 0.9% saline 
solution, 150 mg/kg 5-fluorouracil (5-FU; Accord Healthcare, Middlesex, UK), 
15 mg/kg oxaliplatin (Hospira UK, Warwickshire, UK), or 200 mg/kg irinotecan 
(Hospira UK, Warwickshire, UK) (Table 2). Prior to the irinotecan 
administration, the animals were injected with 0.01 mg/kg atropine (Leiras, 
Espoo, Finland) subcutaneously to reduce the irinotecan-induced cholinergic 
reaction. 
 
Table 2. Study groups and drug injections in Study I/II 
Groups n Drug injection (i.p.) 
Control 12 0.9% saline 
5-FU 12 150 mg/kg 5-fluorouracil 
Oxaliplatin 12 15 mg/kg oxaliplatin 
Irinotecan 12 200 mg/kg irinotecan (+ 0.01 mg/kg s.c. atropine) 
 
All animals were euthanized after a 72-h observation period during which they 
were weighted and scored for signs of diarrhea daily. Intestinal permeability 
measurement was started 48 h after drug injections. At euthanasia, serum, 
urine, fecal, and intestinal tissue samples were collected for later analyses. The 
study design is depicted in Figure 4. 
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4.2.2 Study III 
In Study III, the study subjects were allocated into two groups: those who 
reported to experience gastrointestinal symptoms at least 50% of their runs 
(symptomatic, n = 8) and those who said to experience gastrointestinal 
symptoms in less than 10% of their runs (asymptomatic, n = 9) (Table 3). 
Intestinal permeability was measured at baseline and after a running test where 
the subjects were asked to run for 90 minutes at a speed equivalent to 80% of 
their best 10 km race time. Serum samples were collected by a licensed physician 
at baseline and immediately after the running test. The subjects were also asked 
to provide a fecal sample at baseline and after the running test. The study design 
is depicted in Figure 4. 
 
Table 3. Study groups and criteria for group allocations in Study III 
Groups n Criteria for group allocations 
Asymptomatic 9 Experiences gastrointestinal symptoms < 10% of runs 
Symptomatic 8 Experiences gastrointestinal symptoms t 50% of runs 
 
4.2.3 Study IV 
In Study IV, murine jejunal tissues were harvested and mounted in Ussing 
chambers for the measurement of intestinal permeability and 
electrophysiological parameters. Both intact jejunal segments and mucosal 
segments stripped of the seromuscular layer were treated with 3 mM DCA 
(Sodium deoxycholate; Sigma-Aldrich, St. Louis, MO, USA) on the luminal side 
for 20 min after which tissue permeability to fluorescein was measured for 105 
min. In a set of experiments, prior to DCA-treatment, the intestinal segments 
were treated with 1 μM tetrodotoxin (TTX; Tetrodotoxin citrate; Ascent 
Scientific, Bristol, UK) for 20 min to eliminate neural activity (Table 3). The 
study design is illustrated in Figure 4. 
MATERIALS AND METHODS 
 46 
 
Table 4. Study groups and in vitro treatment in Ussing chamber in Study IV 
Groups n In vitro treatment in Ussing chamber 
Mucosal 12 - 
Mucosal + DCA 12 3 mM DCA for 20 min 
Intact 22 - 
Intact + DCA 22 3 mM DCA for 20 min 
Intact + TTX 10 1 μM TTX for 20 min 
Intact + TTX +DCA 10 1 μM TTX for 20 min + 3 mM DCA for 20 min 
 
 
 
Figure 4. Flow charts illustrating the study designs of Studies I/II, 
III, and IV. 
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4.3 Sample collection and analyses 
4.3.1 Measurement of in vivo intestinal permeability 
In vivo intestinal permeability to iohexol was measured in Studies I/II and III.  
In Study I/II, the rats received 1 ml of 647 mg/ml iohexol solution (Omnipaque 
300™, GE Healthcare, Oslo, Norway) by oral gavage after which they were 
immediately placed in individual metabolic cages. After 24 h, the total amount 
of excreted urine was measured and stored in -18°C for the analysis of iohexol.  
In Study III, the study subjects ingested 50 ml of 755 mg iohexol/ml solution 
(Omnipaque 350™, GE Healthcare, Oslo, Norway) dissolved in tap water at the 
baseline measurements and just before the running test. They were given 
specimen containers in which they were instructed to collect all excreted urine 
for 24 h at home. Upon returning the specimen containers, the total amount of 
excreted urine was measured, stirred, and a 5-ml sample was taken and stored 
in -18°C for iohexol analysis. 
The concentration of urinary iohexol was analyzed using a commercial ELISA 
kit according to the manufacturer’s instructions (BioPAL Inc., Worcester, MA, 
USA). Intestinal permeability to iohexol was determined by calculating the 
percentage of excreted iohexol using the following equation: 
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4.3.2 Tissue preparation for the Ussing chamber 
Following euthanasia, fresh segments of murine jejunum were harvested by 
removing the entire small intestine and dissecting the four middle-most 
segments. The segments were pinned onto a Sylgard dish with ice cold Ringer 
solution (120 mM NaCl, 5 mM KCl, 25 mM NaHCO3, 1.8 mM Na2HPO4, 0.2 mM 
NaH2PO4, 1.25 mM CaCl2, 1 mM MgSO4, and 10 mM glucose), removed of 
mesenteric fat, and opened along the mesenteric border. After flushing the 
segments free of any intestinal content, the jejunal tissues were either mounted 
into the Ussing chamber system (intact samples) or stripped of their 
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seromuscular layer (mucosal samples). The seromuscular stripping was done by 
pinning the intestinal segment tightly onto the Sylgard plate with the 
seromuscular layer facing upwards. The muscle layer was then carefully 
removed with fine forceps under a stereomicroscope. Immediately after 
seromuscular stripping, the mucosal tissue segments were pinned onto 0.3 cm2 
sliders and mounted into an Ussing chamber system with a voltage-clamp 
apparatus (EasyMount, Physiological Instruments, San Diego, CA, USA). 
4.3.3  Measurement of in vitro intestinal permeability in the Ussing chamber 
 After the prepared tissue segments were mounted onto the Ussing chambers, 
each chamber half was filled with 5 ml Ringer solution to fully immerse the 
tissues in physiological solution. The whole system was water-jacketed to +37°C 
and a carbogen (95% O2 – 5% CO2, AGA, Riihimäki, Finland) flow was applied 
to each chamber. The system could equilibrate for 10 min before the start of any 
protocols. 
Sodium fluorescein (Sigma-Aldrich) was added to the luminal chamber to a 
final concentration of 2 μg/ml. Tissue permeability was measured by taking a 
sample from the serosal chamber at 15, 45, 75, and 105 min and detecting sample 
fluorescence with a Wallac Victor2 1420 Multilabel counter (Perkin-Elmer, 
Waltham, MA, USA) using an excitation/emission wavelengths of 485/535 nm. 
The concentration of fluorescein was calculated from a standard curve and total 
tissue permeability to fluorescein was determined by establishing an apparent 
permeability coefficient (Papp) for each tissue segment using the following 
equation: 
 ൌ ൬൰ כ  ሺ
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,where dc/dt is the change in concentration per unit time in the serosal 
chamber, V is the volume of the serosal chamber (5 ml), A is the surface area of 
the tissue (0.3 cm2), and C is the initial concentration of fluorescein in the 
luminal chamber (2 μg/ml). The Papp value of an individual tissue segment was 
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obtained by averaging the measured Papp values in each time point (15, 45, 75, 
and 105 min). 
4.3.4 Measurement of electrophysiological parameters in the Ussing 
chamber 
All Ussing chamber experiments were carried out under voltage-clamp 
conditions. Short-circuit current (Isc) and transepithelial resistance (TER) were 
monitored and recorded throughout each experiment with Acquire and 
Analyze 2.3 software (Physiological Instruments). The Isc was generated 
through Ag/AgCl electrodes connected to the chamber halves via 4% agar–3 M 
KCl salt bridges. Every 20 s the system was pulsed with a 5-mV step change in 
voltage-clamp mode and the resulting change in Isc was used to obtain the TER 
value of the tissue. The Isc and TER values for each time point were acquired by 
averaging the Isc and TER values between two adjacent time points. 
4.3.5 Tissue collection for histological analysis 
Intestinal tissue was collected for histological analyses in Studies I/II and IV. 
In Study I/II, the entire intestine was removed and 1 cm segments from the 
middle of the jejunum as well as the colon were dissected. The tissue segments 
were cut open and flushed free of intestinal content with cold phosphate-
buffered saline (PBS) solution. 
In Study IV, the jejunal tissues were prepared as described in chapter 4.3.2. 
Tissue preparation for the Ussing chamber. 
For histological analysis, the tissues were fixed in 10% neutral buffered 
formaldehyde (Sigma-Aldrich) for 24–48 h, embedded in paraffin, cut on 
microscopic slides, and stained with hematoxylin–eosin (HE). 
4.3.6 Histological analysis 
Detailed histological analysis of jejunum and colon was performed in Study I/II. 
The analysis was made in a partly blinded manner by a trained pathologist from 
the Faculty of Veterinary Medicine, University of Helsinki. Histological images 
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were acquired with Axio Imager. A2 microscope (20x objective; Carl Zeiss, 
Goettingen, Germany). 
The jejunal samples were analyzed for six change categories: villous stunting, 
villous epithelial injury, crypt hyperplasia, crypt epithelial injury, Paneth cell 
injury, and leukocyte infiltration in lamina propria. Comparable change 
categories were employed for the colon: surface epithelial injury, crypt 
hyperplasia, crypt dilatation and distortion, crypt epithelial injury, crypt loss 
(atrophy), and leukocyte infiltration in lamina propria. Each change category 
was scored on a five-tier scale: no changes (0), minimal (1), mild (2), moderate 
(3) and marked (4). Additionally, we created an overall score for acute jejunal 
and colonic injury. For acute jejunal injury, the grades of villous epithelial 
injury, villous stunting, crypt epithelial injury, and Paneth cell injury were 
combined and averaged. Similarly, the grades of surface epithelial injury, crypt 
epithelial injury, and crypt loss were combined and averaged to obtain a score 
for acute colonic injury. 
4.3.7 Immunofluorescence analysis for enteric nerves 
Immunofluorescence assay for the presence of enteric nerves in jejunal tissues 
was performed in Study IV. 
First, the jejunal tissue samples were deparaffinized and boiled in 10 mM citrate 
buffer for 15 min for antigen retrieval. After washing the samples with PBS twice 
for 5 min, the sections were blocked with 5% normal goat serum (NGS) in PBS-
T (0.3% Triton X-100) for 1 h at room temperature. Next, mouse monoclonal 
13AA8 antineurofilament primary antibody was added in a 1:10 dilution 
(Virtanen et al., 1985; Ylikoski et al., 1990) in PBS-T with 1% NGS for overnight 
at +4°C. The tissue segments were then washed with PBS-T (3 * 10 min) before 
the addition of the secondary antibody goat antimouse-Alexa 488 (1:1000 
dilution; Invitrogen, Carlsbad, CA, USA) in PBS-T with 1% NGS for 1 h at room 
temperature. Once again, the sections were washed with PBS-T (3 * 10 min) after 
which they were covered with 50% glycerol, and imaged with a fluorescence 
microscope (Axio Imager M2; Carl Zeiss, Oberkochen, Germany). 
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4.3.8 Global metabolome analysis of serum and urine 
Global metabolic changes were analyzed from serum and urine with 1mm 
proton nuclear magnetic resonance (1H-NMR) technique in Study I/II. 
The serum samples were prepared for 1H-NMR analysis by mixing 20 μl of serum 
with 2.5 μl 2.5 mM sodium-3ʹ-trimethylsilylpropionate-2,2,3,3-d4 (TSP) in 
deuterium oxide (D2O). For urine samples, 2 μl of a phosphate buffer solution 
(0.06 M Na2HPO4 / 0.04 M NaH2PO4, pH 7) and 2.5 mM TSP were added to 
overcome the pH variation problem. The reason for the addition of TSP into the 
mixture is that it acts as standard compound in chemical shift referencing 
because TSP signal is always in the same position and does not overlap with 
other signals. Thus, other signals can be assigned relative to TSP signal.  
1H-NMR spectral acquisition was done with a standard one-dimensional pulse 
sequence with water suppression (Bruker Avance 600 spectrometer operating 
at 600.13 MHz with a 1-mm 1H/13C/15N TXI probe) at a nominal temperature of 
310K. The acquired spectra were processed using MestReNova 8.1 (Mestrelab 
Research S.L., Spain). The resonances between 0.50-9.5 ppm were binned into 
0.01-ppm buckets, mean-centered for multivariate analysis, and normalized to 
total aliphatic spectral area (0.50-4.30 ppm) to eliminate differences in total 
metabolite concentration. Peaks were assigned to their corresponding 
metabolites using data from literature and a commercial resonance database 
Chenomx (Chenomx NMR 7.6). Peak areas were integrated to calculate the 
relative concentrations. Overall, a total of 66 and 111 spectral regions for serum 
and urine, respectively, were transferred to MATLAB (MathWorks) for data 
analysis.  
4.3.9 Fecal microbiota analysis 
The composition of fecal microbiota was analyzed using 16S rRNA gene 
sequencing in Study I/II. Fecal samples were collected from the metabolic cage 
at baseline and at the end of experiment and stored in -80°C before analysis. 
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The microbial DNA from rat fecal samples was purified using a commercial kit 
(QIAamp DNA Minikit, Qiagen, Doncaster, UK). The total DNA concentration 
of each sample was determined with Quant-iT™ PicoGreen® Assay (Invitrogen, 
Eugene, OR, USA) and the samples were diluted to a concentration of 1 ng/μl 
prior to 16S rRNA gene sequencing on the Illumina HiSeq2500 platform.     
After a two-step PCR amplification protocol, the Illumina Nextera Kit was used 
to construct the DNA libraries. Paired-end sequencing of 200-nt-reads was 
performed. In total, the sequencing produced 9 698 319 reads which were 
processed using the R package mare (Korpela, 2016; R Development Core Team, 
2008). The reads were filtered for quality and chimeras (UCHIME in the de novo 
mode) (Edgar et al., 2011) and subsequently annotated taxonomically using 
UPARSE (confidence cut-off at 0.5) (Edgar, 2013) with RDP as the reference 
database. 
4.3.10 Biochemical analyses 
Serum concentration of zonulin was measured using commercial ELISA kits 
(Rat: BlueGene, Shanghai, China; Human: Immunodiagnostik, Bensheim, 
Germany) in Studies I/II and III. 
Serum concentration of intestinal fatty acid-binding protein (I-FABP) was 
analyzed using a commercial ELISA kit (Hycult Biotech, Uden, the Netherlands) 
in Study III. 
Serum bacterial lipopolysaccharide (LPS) activity was quantified using a 
commercial Limulus Amebocyte Lysate (LAL) Chromogenic Endpoint Assay 
(Hycult biotech) in Study III. 
In Study III, the study subjects were given written instructions to collect a fecal 
sample at home in a provided specimen container. Fecal concentration of 
calprotectin was measured with Calpro ELISA test (Calpro AS, Oslo Norway). 
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4.3.11 Assessment of clinical signs of gastrointestinal distress 
In Study I/II, the animals were checked for diarrhea daily. The severity of 
diarrhea was scored on four-tier scale: no diarrhea (0), mild diarrhea (1), 
moderate diarrhea (2), and severe diarrhea (3). Grading was based on the extent 
of fecal staining and on the viscosity of the fecal matter. 
In Study III, the assessment of gastrointestinal symptoms was performed in the 
form of questionnaires. At the beginning of the study, the study subjects filled 
out a background questionnaire probing the frequency of gastrointestinal 
symptoms during running. The subjects were also asked to rate their typical 
stool consistency after running. The results of this questionnaire were used to 
allocate the subjects to the two study groups. After the running test, the 
participants filled out another questionnaire asking if they had experienced 
gastrointestinal symptoms during the running test and if they experienced 
symptoms later that day. They also graded the amount of stomach pain they 
experienced during the running test on a visual analog scale (VAS) from 0 to 10 
and rated the consistency of the first stool after the running test. 
4.3.12 Data analyses  
Statistical analyses were performed with PASW Statistics software versions 
18.0.2 and 22.0 (IBM, Armonk, NY, USA) unless stated otherwise. All data were 
deemed significant when P < 0.05. 
In Studies I/II and IV, the differences in measured variables (excluding fecal 
microbiota and metabolic analyses) between groups were first analyzed with 
non-parametric Kruskal-Wallis test and if global P < 0.05, the differences 
between individual groups were calculated using the Mann–Whitney U-test. In 
Study III with only two experimental groups, the differences between groups 
were analyzed using independent samples t-test. Paired t-test was used to 
analyze the changes within groups from baseline to after the running test. 
The statistical analysis of the fecal microbiota data was performed using R 
package mare. The mare package was used to create the taxonomic tables, count 
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the relative abundances of each taxon, and calculate the inverse Simpson 
diversity index. Treatment-induced changes in the relative abundances of 
bacterial taxa from baseline were identified using the change test script with 
false discovery rate correction (FDR) in the mare package. The Kruskal-Wallis 
test with Dunn-Bonferroni post hoc test was used to analyze the differences in 
the relative abundances of bacterial taxa between the groups at baseline and at 
the end of the experiment. Group differences in inverse Simpson diversity index 
were analyzed with one-way ANOVA followed by Bonferroni post hoc test.  
Multivariate paired analysis with Bonferroni correction was used to calculate 
the differences in relative metabolite concentrations between the groups. To 
visualize the metabolic alterations between groups, principle component 
analysis (PCA) and partial least squares-discriminant analysis (PLS-DA) were 
performed using in-house MATLAB scripts and PLS Toolbox (Eigenvector 
Research, Manson, WA, USA). The variable importance in the projection (VIP) 
scores were obtained from the PLS-DA model and variables with a VIP score t 
1 were considered relevant for group discrimination. 
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Table 5. Summary of collected samples and measured variables in each study 
 Study I/II Study III Study IV 
Species (n) Rat (48) Human (17) Mouse (11) 
Study type In vivo In vivo In vitro 
Samples Serum 
Urine 
Feces 
Intestinal tissue 
Serum 
Urine 
Feces 
Jejunal tissue 
Measured 
variables 
Clinical signs: 
Body weight 
change 
Severity of 
diarrhea 
Serum: 
Zonulin 
Global 
metabolome 
Urine: 
Intestinal 
permeability to 
iohexol  
Global 
metabolome 
Feces: 
Fecal microbiota 
composition 
Intestinal 
tissues: 
Histological 
analyses of 
jejunum and 
colon 
Clinical signs: 
Occurrence of 
gastrointestinal 
symptoms 
Severity of 
stomach pain 
Stool consistency 
Serum: 
Intestinal fatty 
acid-binding 
protein (I-FABP) 
Bacterial 
lipopolysaccharide 
activity (LPS) 
Zonulin 
Urine: 
Intestinal 
permeability to 
iohexol 
Feces: 
Calprotectin 
Electrophysiological 
parameters: 
Short-circuit current 
(Isc) 
Transepithelial 
resistance (TER) 
Tissue permeability: 
Permeability to 
fluorescein 
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5 RESULTS  
5.1 Clinical signs of gastrointestinal distress 
5.1.1 Chemotherapeutics induce body weight loss and diarrhea 
All the administered chemotherapeutics induced significant (P < 0.001) body 
weight loss in the experimental animals during the 72-h experimental protocol 
compared to the Control group (Figure 5). Irinotecan administration reduced 
the animals’ body weight by 16.0 r 3.5% which was significantly (P < 0.001) more 
compared to either 5-FU (6.6 r 2.3%) or oxaliplatin (11.6 r 3.4%) administration. 
The Control group maintained their body weight during the experiment. 
 
 
Figure 5. A single intraperitoneal injection of 5-fluorouracil (5-
FU), oxaliplatin, or irinotecan on Day 0 significantly decreased the 
animals’ body weight (%) already after 24 hours (Day 1). At the end 
of the experiment on Day 3, the animals in the Irinotecan group had 
lost significantly more of their body weight than animals that 
received either 5-FU or oxaliplatin. Oxaliplatin also induced 
significantly more severe body weight loss than 5-FU. Line graph 
shows medians with interquartile ranges. ***P < 0.001 compared to 
all other groups, **P < 0.01 between groups. n = 12 in all groups, 
except in Oxaliplatin where n = 10. Modified from a figure originally 
appearing in Cancer Chemotherapy and Pharmacology (78:863-
874, 2016) and reprinted under the Creative Commons license. 
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Most of the animals that received chemotherapeutic agents also exhibited 
diarrhea over the course of the experiment (Figure 6). In the Irinotecan group, 
67% of the animals developed severe diarrhea, 25% moderate diarrhea, and 8% 
mild diarrhea. Animals that received oxaliplatin exhibited mainly moderate 
diarrhea (80%) with one case of both mild and severe diarrhea. In the 5-FU 
group, 50% of the animals had mild diarrhea. The Control group did not show 
any signs of diarrhea. 
 
 
Figure 6. Diarrhea incidence (%) in the experimental groups over 
the course of the experiment (72 h). Administration of 5-FU induced 
mild diarrhea in half of the animals whereas most of the animals in 
the Oxaliplatin and Irinotecan groups exhibited moderate or severe 
diarrhea. n = 12 in all groups, except in Oxaliplatin where n = 10. 
Modified from a figure originally appearing in Cancer 
Chemotherapy and Pharmacology (78:863-874, 2016) and reprinted 
under the Creative Commons license. 
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5.1.2 Gastrointestinal symptoms during and after a 90-min running test 
Overall, 3/9 runners in the asymptomatic group and 5/8 runners in the 
symptomatic group reported some degree of stomach pain during the running 
test. When scored on the VAS, the symptomatic runners had an average 
stomach pain of 2.0 r 2.1 which was higher than asymptomatic runners (0.30 r 
0.56) but the difference did not reach statistical significance (P < 0.061) (Figure 
7). 
In the symptom questionnaire, all symptomatic runners and 5/9 asymptomatic 
runners reported to have experienced at least one gastrointestinal symptoms 
during or following the running test. Results of the symptom questionnaire are 
summarized in Table 6. 
 
 
Figure 7. A total of five symptomatic runners and three 
asymptomatic runners reported at least some degree of stomach 
pain (VAS, 0-10) during the 90-min running test at a challenging 
pace.   
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Table 6. The occurrence of gastrointestinal symptoms during and following the 
running test 
Symptom Asymptomatic Symptomatic 
Nausea 0/9 3/8 
Burping 1/9 3/8 
Heartburn 0/9 1/8 
Throwing up 0/9 0/8 
Bloating 0/9 2/8 
Liquid in stomach 0/9 1/8 
Flatulence 4/9 4/8 
Diarrhea 1/9 3/8 
Constipation 1/9 2/8 
Subjects reporting at 
least one symptom 
5/9 8/8 
 
 
5.2 Histological analyses of intestinal tissues 
5.2.1 Chemotherapeutics disrupt intestinal morphology 
Administration of the chemotherapeutic agents to the experimental animals 
resulted in significant tissue damage in both the jejunum and the colon (Table 
7). Based on the acute injury score (Figure 8), oxaliplatin produced significantly 
(P < 0.001) more histopathological changes in the jejunum than 5-FU and 
irinotecan whereas irinotecan was significantly more toxic in the colon than 
oxaliplatin (P < 0.05) and 5-FU (P < 0.001). No histological changes were 
observed in the Control group. 
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Table 7. Histological grades of chemotherapy-induced tissue damage 
Change category 5-FU Oxaliplatin Irinotecan 
Jejunum    
Villous stunting 2.8 r 1.1a  3.6 r 0.52a,b 2.7 r 0.65b 
Villous epithelial 
injury 2.3 r 1.3a 3.5 r 0.70a,b 2.3 r 0.45b 
Crypt hyperplasia 0.75 r 1.1b 1.5 r 1.1a  2.5 r 0.52a,b 
Crypt injury 2.9 r 0.79a 4.0 r 0.0a,c 2.7 r 0.49c 
Paneth cell injury 2.3 r 0.49a,c 2.8 r 0.42a,c 0c 
Lamina propria 
leukocytes 2.9 r 0.51b,c 4.0 r 0.0c 1.6 r 1.2b,c 
Colon    
Surface epithelial 
injury 1.3 r 0.62a,c 1.9 r 0.87a 2.3 r 0.49c 
Crypt hyperplasia 1.7 r 0.78 2.0 r 0.0a 1.0 r 1.0a 
Crypt dilatation and 
distortion 2.3 r 0.65 1.8 r 0.63 2.2 r 0.39 
Crypt injury 1.8 r 0.45b 2.2 r 0.63 2.7 r 0.65b 
Crypt atrophy 0b 0b 0.83 r 1.0b 
Lamina propria 
leukocytes 0.33 r 0.78c 0.80 r 1.0a 1.9 r 0.67a,c 
Values are expressed as means r standard deviations. 1 = minimal, 2 = mild, 3 = 
moderate, 4 = marked. aP < 0.05 between groups, bP < 0.01 between groups, cP < 
0.001 between groups. 
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Figure 8. After histological examination of the intestinal tissues, 
acute jejunal (A) and colonic (B) injury scores were calculated for 
each treatment group. Oxaliplatin caused significantly more acute 
injury in the jejunum than 5-FU and irinotecan. In the colon, 
however, irinotecan administration produced the most severe 
damage. Box plots show median with upper and lower quartiles. 
Whiskers represent minimum and maximum. *P < 0.05, ***P < 
0.001. n = 12 in all groups, except in Oxaliplatin where n = 10. 
Modified from a figure originally appearing in Cancer 
Chemotherapy and Pharmacology (78:863-874, 2016) and reprinted 
under the Creative Commons license. 
 
5.3 Measurements of intestinal permeability 
5.3.1 Chemotherapeutics increase in vivo intestinal permeability to iohexol 
Intestinal permeability to iohexol was significantly (P < 0.001) increased in all 
chemotherapy-treated groups compared to the Control group (Figure 9). In 
addition, the Irinotecan group (8.1 r 8.9%) exhibited significantly (P < 0.001) 
higher iohexol permeability than animals that received 5-FU (1.6 r 1.5%) or 
oxaliplatin (2.6 r 1.5%). At baseline, there were no differences in iohexol 
permeability between the groups (data not shown). 
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Iohexol permeability showed an inverse correlation with chemotherapy-
induced body weight loss (Spearman’s U = -0.873, P < 0.001) as well as a positive 
correlation with both diarrhea scores (Spearman’s U = 0.815, P < 0.001) and acute 
colonic injury scores (Spearman’s U = 0.807, P < 0.001) (Figure 10). There was 
also a positive correlation between acute jejunal injury score and iohexol 
permeability (Spearman’s U = 0.525, P < 0.001) but this correlation exhibited a 
very low coefficient of determination (r2 = 0.05, P < 0.13) indicating low 
dependency between the two variables (Figure 10C). 
 
 
Figure 9. Intestinal permeability to iohexol (% of administered 
iohexol) at the end of experiment (72 h). Animals that received 
chemotherapeutics exhibited significantly higher iohexol 
permeability compared to the control animals. Of the studied 
chemotherapeutics, irinotecan induced the highest increase in 
iohexol permeability. Box plots show median with upper and lower 
quartiles. Whiskers represent minimum and maximum. *P < 0.05 
between groups, ***P < 0.001 compared to all other groups. n = 12 
in Control, n = 11 in 5-FU, n = 10 in Oxaliplatin, and n = 9 in 
Irinotecan. Modified from a figure originally appearing in Cancer 
Chemotherapy and Pharmacology (78:863-874, 2016) and reprinted 
under the Creative Commons license. 
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Figure 10. Spearman’s correlations between iohexol permeability 
(%) and body weight change (A), diarrhea scores (B), acute jejunal 
injury scores (C), and acute colonic injury scores (D). Black dots 
represent samples from the Control group, green dots from the 5-
FU group, orange dots from the Oxaliplatin group, and purple dots 
from the Irinotecan group. Modified from a figure originally 
appearing in Cancer Chemotherapy and Pharmacology (78:863-
874, 2016) and reprinted under the Creative Commons license. 
 
5.3.2  Running increases in vivo intestinal permeability to iohexol 
Running for 90 minutes at a challenging pace significantly (P < 0.001) increased 
intestinal permeability to iohexol (Figure 11). However, there was no significant 
difference in the mean increase in iohexol permeability between the 
asymptomatic (0.19 r 0.18%) and the symptomatic (0.16 r 0.15%) runners. 
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Figure 11. Running for 90 minutes significantly increased 
intestinal permeability to iohexol (% of administered iohexol) in 
both study groups. Blue dots represent individual values from the 
asymptomatic group and red dots from the symptomatic group. 
The lines connecting the dots indicate the change from the baseline 
in each individual. ***P < 0.001. n = 9 in the asymptomatic, n = 8 in 
the symptomatic. 
 
5.3.3 DCA increases ex vivo permeability to fluorescein in mucosal segments 
Subjecting jejunal mucosal tissues to DCA concentrations relating to high-fat 
feeding for 20 min significantly (P < 0.001) increased permeability to fluorescein 
(26.5 r 3.2 * 10-3 cm/h) compared to non-treated mucosal segments (19.5 r 3.0 * 
10-3 cm/h) (Figure 12). In the intact tissues, DCA treatment did not increase 
fluorescein permeability (Figure 12) but resulted in a significant (P < 0.001) 
increase in tissue TER values (17.5 r 11.8 :/cm2) compared to spontaneous 
changes in TER values observed in the control tissues (-1.4 r 3.2 :/cm2) (Figure 
13). Treating the intact tissues with TTX to eliminate neural activity prior to 
exposure to DCA significantly (P < 0.001) attenuated the DCA-induced increase 
in TER values (4.8 r 9.3 :/cm2). 
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Figure 12. Treating jejunal tissue segments stripped of 
seromuscular layers (Mucosal) with 3 mM deoxycholic acid (DCA) 
for 20 minutes in Ussing chambers significantly increased tissue 
permeability to fluorescein. No changes in fluorescein permeability 
were observed in intact jejunal tissues treated with DCA or in intact 
tissues treated with 1 μM tetrodotoxin (TTX) prior to DCA-
treatment. Box plots show median with upper and lower quartiles. 
Whiskers represent minimum and maximum. ***P < 0.001 
compared to all other groups. n = 9-22. 
 
Figure 13. Exposing jejunal tissue segments to 3 mM deoxycholic 
acid (DCA) for 20 minutes in Ussing chambers resulted in a 
significant increase in transepithelial resistance (TER). Tissue 
segments treated with 1 μM tetrodotoxin (TTX) prior to DCA 
treatment exhibited a significantly attenuated response to DCA. 
Box plots show median with upper and lower quartiles. Whiskers 
represent minimum and maximum. *P < 0.05, ***p < 0.001 
compared to all other groups. n = 9-22. 
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5.4 Analysis of fecal microbiota 
5.4.1 Irinotecan modulates the composition of fecal microbiota 
Irinotecan administration significantly (P < 0.01) decreased the diversity of fecal 
microbiota (calculated as inverse Simpson Index) compared to other treatment 
groups (Figure 14A). Inverse Simpson Index showed an inverse correlation with 
iohexol permeability (Spearman’s U = -0.412, P < 0.01) (Figure 14B). 
 
 
Figure 14. Irinotecan treatment resulted in a significant reduction 
in fecal microbial diversity (inverse Simpson Index) after 72 hours 
(A). The diversity of fecal microbiota at the end of the experiment 
showed an inverse correlation with intestinal permeability to 
iohexol (B). Black dots represent samples from the Control group, 
green dots from the 5-FU group, orange dots from the Oxaliplatin 
group, and purple dots from the Irinotecan group. Box plots show 
median with upper and lower quartiles. Whiskers represent 
minimum and maximum. **P < 0.01 compared to all other groups. 
n = 7-11. Modified from two figures originally appearing in Cancer 
Chemotherapy and Pharmacology (80:317-332, 2017) and reprinted 
under the Creative Commons license. 
   
At the phylum level, irinotecan significantly altered the composition of fecal 
microbiota by reducing the relative abundances of Actinobacteria (P < 0.05), 
Bacteroidetes (P < 0.001), and Synergistetes (P < 0.001) while increasing the 
relative proportions of Proteobacteria (P < 0.01) and Fusobacteria (P < 0.001) 
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compared to the Control group (Table 8). The genus level analysis revealed that 
the irinotecan-induced increase in the relative abundance of Proteobacteria was 
mostly driven by a significant (P < 0.01) increase in Escherichia/Shigella spp. 
 
Table 8. Phylum level changes in the relative abundances (%) of each bacterial 
taxon  
Phylum Control 5-FU Oxaliplatin Irinotecan 
Actinobacteria -5.9 ± 6.0%a 0.01 ± 3.3% -9.4 ± 10.7% -8.0 ± 9.5%a 
Bacteroidetes 4.1 ± 23.4%c 19.7 ± 19.1%c 10.4 ± 18.0%c -16.4 ± 22.0%c,c,c 
Firmicutes -1.9 ± 28.6% -27.8 ± 18.8% -19.7 ± 25.8% -1.8 ± 62.5% 
Fusobacteria 0.0 ± 0.1%c 0.0 ± 0.03%b 0.05 ± 5.5% 13.9 ± 16.1%b,c 
Proteobacteria 0.6 ± 1.0%b 4.8 ± 9.0% 8.8 ± 18.7% 10.2 ± 38.5%b 
Synergistetes 0.4 ± 0.8%c 0.55 ± 0.85%b 0.15 ± 1.2% -0.7 ± 0.8%b,c 
Verrucomicrobia 0.4 ± 0.3%b 2.0 ± 2.1%a,b 0.8 ± 3.2% 0.1 ± 1.2%a 
Values are expressed as means r standard deviations. aP < 0.05 between groups, 
bP < 0.01 between groups, cP < 0.001 between groups. Modified from a table 
originally appearing in Cancer Chemotherapy and Pharmacology (80:317-332, 
2017) and reprinted under the Creative Commons license. 
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5.5 Analysis of global metabolome 
5.5.1 Chemotherapeutics change the global metabolic profile of serum and 
urine 
PCA of serum and urine revealed that the chemotherapy groups were 
metabolically different from the Control group at the end of experiment (Figure 
15). In the serum analysis, the control samples formed a separate cluster away 
from the baseline samples indicating also time-dependent changes in the 
metabolome. VIP scores derived from PLS-DA modeling of serum and urine 
metabolome indicated several metabolites that were relevant for the observed 
discrimination between the Control group and each treatment group (Figure 
16). 
 
 
Figure 15. Principal component analysis (PCA) of the serum 
metabolome (A) showed both time-dependent and 
chemotherapeutics-induced changes at the end of the experiment 
(t2, filled-out shapes). The urine metabolome (B) exhibited only 
chemotherapy-related alterations. At baseline (t1, empty shapes), 
the groups clustered together in both analyses exhibiting metabolic 
similarity. PC = principal component. Modified from a figure 
originally appearing in Cancer Chemotherapy and Pharmacology 
(80:317-332, 2017) and reprinted under the Creative Commons 
license. 
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Figure 16. Variable importance in the projection (VIP) scores 
derived from partial least squares-discriminant analyses (PLS-DA) 
of serum (left panel: A, C, E) and urine (right panel: B, D, F). VIP 
scores indicate the individual metabolites that are the most 
relevant for discrimination between each treatment group (5-FU: 
A, B; Oxaliplatin: C, D; Irinotecan: E, F) and the Control group. The 
color of the dots depicts the direction of the metabolic change 
relative to the Control group (green dots: significant increase in 
metabolite’s resonance intensity compared to the Control group; 
red dots: significant decrease in metabolite’s resonance intensity 
compared to the Control group). 
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5.5.2  Chemotherapeutics increase serum levels of fatty acid and N(CH3)3 
moieties 
All the administered chemotherapeutics significantly increased the serum 
levels of fatty acid moieties -CH3 (P < 0.01) and =CH-CH2-CH= (P < 0.001) 
(Figure 17). These moieties correspond to LDL-like lipid particles (-CH3) and 
polyunsaturated fatty acids (PUFAs; =CH-CH2-CH=). Similarly, the animals that 
received chemotherapeutics had significantly (P < 0.001) elevated levels of 
serum N(CH3) moieties compared to control animals (Figure 17C). This moiety 
is present in multiple trimethylamine- and choline-containing metabolites.    
5.5.3 Chemotherapeutics decrease urinary hippurate excretion 
The chemotherapy-treated groups excreted significantly (P < 0.001) less 
hippurate in urine than the Control group (Figure 18A). In addition, urinary 
hippurate excretion exhibited a significant inverse correlation with iohexol 
permeability (Spearman’s U = -0.887, P < 0.001) (Figure 18B). 
  
 
Figure 17. Chemotherapeutics significantly increased the serum 
levels of fatty acid moieties -CH3 (A) and =CH-CH2-CH= (B) as well 
as the N(CH3)3 moiety (C). Bars show the mean resonance 
intensities (RI) with the error bars representing standard 
deviations.  *P < 0.05, **P < 0.01, ***P < 0.001. n = 10-12. 
 
 
RESULTS 
 
 71 
 
Figure 18. Chemotherapeutics significantly decreased urinary 
hippurate excretion (A). The excretion of hippurate also showed an 
inverse correlation with intestinal permeability to iohexol (% of 
administered iohexol) (B). Black dots represent samples from the 
Control group, green dots from the 5-FU group, orange dots from 
the Oxaliplatin group, and purple dots from the Irinotecan group. 
Bars show the mean resonance intensity (RI) with the error bars 
indicating standard deviations. ***P < 0.001 compared to all other 
groups. n = 9-12. 
 
5.6 Biochemical analyses 
5.6.1 Running increases serum concentrations of I-FABP 
Overall, running for 90 minutes significantly (P < 0.01) increased serum I-FABP 
concentrations (Figure 19). However, there was no significant difference in the 
mean increase of serum I-FABP concentrations following the running test 
between asymptomatic (490 ± 513 pg/ml) and symptomatic (572 ± 832 pg/ml) 
runners. 
5.6.2 Other biochemical measurements 
Fecal calprotectin concentrations showed a non-significant (P = 0.058) increase 
from baseline after the 90-min running test (Figure 20). 
Running for 90 minutes did not increase serum LPS activity but symptomatic 
runners exhibited significantly (P < 0.01) higher serum LPS activity at baseline 
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than their asymptomatic counterparts (Figure 21). After the running test, there 
was no difference in serum LPS activity between the groups. 
 
 
Figure 19. Running for 90 minutes significantly increased the 
serum concentration of intestinal fatty acid-binding protein (I-
FABP). Blue dots represent individual values from the 
asymptomatic group and red dots from the symptomatic group. 
The lines connecting the dots indicate the change from the baseline 
in each individual. **P < 0.01. n = 9 in the asymptomatic, n = 8 in 
the symptomatic. 
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Figure 20. Fecal calprotectin concentration tended to increase 
after a 90-min running test. Blue dots represent individual values 
from the asymptomatic group and red dots from the symptomatic 
group. The lines connecting the dots indicate the change from the 
baseline in each individual. n = 9 in the asymptomatic, n = 8 in the 
symptomatic. 
 
 
Figure 21. Athletes who reported to experience gastrointestinal 
symptoms over 50% of runs (symptomatic) had higher serum 
bacterial lipopolysaccharide (LPS) activity at rest than 
asymptomatic runners. After a 90-min running test, however, both 
groups exhibited similar serum LPS activity. **P < 0.01. 
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6 DISCUSSION 
6.1 Chemotherapy-induced gastrointestinal toxicity 
6.1.1 Experimental models and study setting 
Our results from Study I/II demonstrate the detrimental effects of 
chemotherapy to the intestinal mucosa as the experimental animals that 
received 5-FU, oxaliplatin, or irinotecan exhibited significant body weight loss, 
diarrhea, and intestinal damage. These findings are consistent with other 
animal studies in which body weight loss, varying degrees of diarrhea, and 
histopathological changes in the intestine are commonly observed following the 
administration of 5-FU, oxaliplatin, or irinotecan (Generoso et al., 2015; Justino 
et al., 2014; Kato et al., 2017; Lima-Júnior et al., 2014; Vanhoecke et al., 2015; 
Wang et al., 2015). In clinical studies, gastrointestinal toxicity is usually reported 
as diarrhea incidence and severity, both of which vary greatly depending on the 
chemotherapy-regimen (Andreyev et al., 2014). Across different studies, the 
average incidence of severe diarrhea during chemotherapy seems to be 
approximately 15% (Andreyev et al., 2014; Iacovelli et al., 2014). Interestingly, 
the risk of severe diarrhea during chemotherapy increases with treatments 
containing irinotecan suggesting that irinotecan is particularly damaging to the 
intestine (Andreyev et al., 2014; Iacovelli et al., 2014; Keefe et al., 2014). In our 
study, irinotecan treatment resulted in the most severe form of diarrhea and 
significantly greater acute colonic damage. These two events are likely related 
because fluid adsorption happens mainly in the large intestine. Also, 
mechanistically, irinotecan’s propensity to damage the colon may explain the 
increased incidence of severe diarrhea observed with irinotecan-based 
regimens. 
Although our experimental animals exhibited clear signs of CIGT, it is worth 
considering the clinical relevance of the administered drug doses. We employed 
a single injection model for all chemotherapeutics with doses designed to 
induce gastrointestinal toxicity but not mortality. Our drug administration 
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routes and dose selection was based on previous literature describing the 
gastrointestinal effects of different doses of 5-FU (Cool et al., 2005), oxaliplatin 
(Wang et al., 2015), and irinotecan (Gibson et al., 2007) in rodents. How these 
models compare to the clinical situation is difficult to decipher. Firstly, in 
humans, chemotherapy-regimens usually consist of a combination of drugs 
which are administered intravenously in several cycles over multiple weeks. 
Secondly, human chemotherapy doses are calculated as milligrams per body 
surface area. For example, a commonly used FOLFIRI regimen includes an 
intravenous bolus of 400 mg/m2 and a 46-h intravenous infusion of 2400 mg/m2 
5-FU as well as an intravenous infusion of 180 mg/m2 irinotecan over 90 
minutes. In oxaliplatin-containing regimens such as FOLFOX, the dosage of 
oxaliplatin is usually 85 mg/m2 (personal communication with P. Österlund). 
Estimation on how these doses compare to the doses in our study can be done 
using the following equation (Nair and Jacob, 2016): 
ܪݑ݉ܽ݊݁ݍݑ݅ݒ݈ܽ݁݊ݐ݀݋ݏ݁ሺܪܧܦሻ
ൌ ܣ݈݊݅݉ܽ݀݋ݏ݁݉݃ ݇݃Τ ൈሺܣ݈݊݅݉ܽݓ݄݁݅݃ݐሺ݇݃ሻܪݑ݉ܽ݊ݓ݄݁݅݃ݐሺ݇݃ሻሻ
଴Ǥଷଷ 
Using the average body weight of animals in our study (0,332 kg) and a reference 
human body weight of 60 kg, the HEDs of our doses were 27 mg/kg for 5-FU, 
2.7 mg/kg for oxaliplatin, and 36 mg/kg for irinotecan. These values can further 
be converted to per body surface area values by multiplying them by a 
correction factor of 37 (Nair and Jacob, 2016). This yields the final HED values 
of 1000 mg/m2 for 5-FU, 100 mg/m2 for oxaliplatin, and 1330 mg/m2 for 
irinotecan. These values reveal that our doses for 5-FU and oxaliplatin 
somewhat represent the doses used in common chemotherapy-regimens 
whereas the irinotecan dose was clearly higher than what is normally 
administered to patients. However, considering that pharmacokinetic 
properties of drugs usually differ between species, scaling and directly 
comparing drug doses between humans and rodents should be interpreted 
carefully. 
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6.1.2 Does iohexol permeability reflect the severity of CIGT? 
Our data show that 5-FU, oxaliplatin, and irinotecan increase intestinal 
permeability to iohexol and that iohexol permeability correlates with the 
clinical manifestations of CIGT (body weight loss and diarrhea) and with the 
extent of acute colonic injury. Studies have previously reported increased 
intestinal permeability after the administration of 5-FU (Ferreira et al., 2012; 
Generoso et al., 2015; Justino et al., 2014) and irinotecan (Pedroso et al., 2015; 
Wardill et al., 2016) but, to our knowledge, our study is the first one to show 
increased intestinal permeability following oxaliplatin administration. Overall, 
these data suggest that iohexol permeability could serve as an objective measure 
of CIGT in clinical settings. This idea lends support from previous studies that 
have correlated increases in intestinal permeability after chemotherapy with 
the severity of mucositis (Choi et al., 2007; Melichar et al., 2007) and the 
occurrence of diarrhea (Russo et al., 2013) and nausea (Fazeny-Dörner et al., 
2002). Melichar et al. (2007) even showed that pre-chemotherapy intestinal 
permeability measurements could possibly predict individual patients’ 
susceptibility to CIGT. Thus, measuring intestinal permeability prior to or 
during chemotherapy could help clinicians to adjust dosing individually before 
the onset of severe toxicities. In this regard, iohexol’s main advantage over other 
permeability probes would be that it is already readily available in medical 
facilities due to its routine use as a contrast medium. Iohexol is also easier to 
detect than the commonly used sugar probes that require chromatographic 
equipment for detection. However, considering that the above-mentioned 
studies employed either the L/M -ratio or 51Cr-EDTA as their intestinal 
permeability probe, the use of iohexol permeability in the context of CIGT 
warrants more research. 
6.1.3 What do the microbial and metabolic changes reveal about the 
mechanisms of CIGT? 
Recent studies have highlighted the role of microbiota in chemotherapy-related 
toxicities as chemotherapeutics not only modulate the composition of intestinal 
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microbiota (Touchefeu et al., 2014) but they are also subject to modulation by 
the intestinal microbes themselves (Alexander et al., 2017). Our microbial 
analysis show significant changes in the composition of fecal microbiota 
following the administration of irinotecan. Notably, irinotecan treatment 
reduced the diversity of fecal microbiota and increased the relative abundance 
of Proteobacteria with both events indicating intestinal dysbiosis, a condition 
often associated with intestinal inflammation (Shin et al., 2015; Suchodolski, 
2016). All chemotherapeutics also exhibited significantly decreased urinary 
hippurate excretion which has been associated with intestinal dysbiosis in IBD 
patients (Williams et al., 2010). Fecal microbiota diversity and urinary hippurate 
excretion also correlated with intestinal permeability suggesting that intestinal 
dysbiosis may contribute to the development of CIGT.  
Generally, our microbial data seem to be consistent with other animal studies 
examining irinotecan-induced modifications in fecal microbiota (Lin et al., 2012; 
Stringer et al., 2007; Touchefeu et al., 2014; Vanhoecke et al., 2015). Although 
one should be cautious when comparing changes in gut microbiota between 
species, Proteobacteria seem to be universally elevated in different species 
during intestinal inflammation (Larrosa et al., 2009; Lupp et al., 2007; 
Minamoto et al., 2015; Shin et al., 2015). Additionally, human studies with 
varying chemotherapy-regimens have also reported reduced microbial diversity 
and increased abundance of Proteobacteria following chemotherapy (Alexander 
et al., 2017; Montassier et al., 2015, 2014; Stringer et al., 2013). These are 
interesting findings in the context of CIGT because Proteobacteria produce LPS 
which together with the observed increase in intestinal permeability could lead 
to increased LPS leakage into circulation and subsequent activation of 
inflammatory processes. Indeed, studies have shown increased concentrations 
of blood LPS and pro-inflammatory cytokines after chemotherapy (Cario, 2016; 
Lee et al., 2014; Wardill et al., 2016). Interestingly, improper function of TLR4, 
the major receptor for LPS, protects mice from methotrexate-induced gut 
toxicity (de Koning et al., 2006) and the deletion of the TLR4 gene altogether 
decreases irinotecan-induced gastrointestinal damage (Wardill et al., 2016). 
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Although only irinotecan administration resulted in a statistically significant 
increase in the relative abundance of Proteobacteria, our metabolic analyses 
hint the presence of inflammatory processes in all chemotherapy-treated 
groups. All treatment groups exhibited increased levels of serum fatty acid and 
N(CH3)3 moieties which may be signs of inflammation-mediated lipolysis and 
PUFA generation. Increased plasma concentrations of PUFAs and N(CH3)3 
moieties are also present in IL-10-/- mice which spontaneously develop colitis 
(Martin et al., 2009) suggesting that their increase is due to intestinal 
inflammation. Interestingly, in a previous clinical study, elevated pre-treatment 
levels of -CH3, =CH-CH2-CH=, and N(CH3)3 moieties associated with increased 
incidence of severe toxicities during capecitabine (5-FU pro-drug) treatment 
leading the authors to speculate about underlying inflammation in these 
patients (Backshall et al., 2011). In addition to serum lipids, all chemotherapy-
treated groups in our study exhibited significantly decreased serum levels of 
several amino acids, such as tryptophan and arginine which have been shown 
to participate in inflammatory processes (Gupta et al., 2012; Popovic et al., 
2007). Overall, these findings indicate that the relationship between intestinal 
microbiota, intestinal permeability, and inflammatory signals together 
influence the development of CIGT but the exact causality of this relationship 
is still unclear. 
However, some limitations should be kept in mind when interpreting our 
results. Some of the observed changes may rise from catabolic effects of stress 
and poor nutritional status. The metabolic analyses revealed many metabolic 
alterations that could be related to the stressful experimental conditions, such 
as metabolic caging. Considering that changes in body weight may impact the 
levels of multiple metabolites, it is likely that some of our observed changes in 
the metabolome represent non-specific toxicities to the chemotherapeutics 
(Connor et al., 2004; Serrano-Contreras et al., 2016). Nonetheless, as the 
baseline samples and samples from control animals were also collected 
under/after metabolic caging, the alterations in the metabolome can, at least 
partly, be attributed to the chemotherapeutics. 
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6.2 Running-induced gastrointestinal distress 
6.2.1 Does intestinal permeability explain gastrointestinal symptoms during 
running? 
Our results from Study III show that running for 90 min at a challenging pace 
increases intestinal permeability to iohexol. Previous studies on this subject 
have reported mixed findings (Davison et al., 2016; JanssenDuijghuijsen et al., 
2017; March et al., 2017; Marchbank et al., 2011; Pals et al., 1997; Ryan et al., 1996; 
van Nieuwenhoven et al., 2004, 1999; van Wijck et al., 2012b; van Wijck et al., 
2011; Zuhl et al., 2015) but to our knowledge, our study is the first to directly 
compare running-induced changes in intestinal permeability in asymptomatic 
and symptomatic athletes. Our data suggest that changes in intestinal 
permeability do not explain the development of gastrointestinal symptoms 
during running as we observed no differences between asymptomatic and 
symptomatic runners. However, there are several factors that should be 
considered when interpreting these results. 
Firstly, although we instructed the athletes to run at a challenging pace, we did 
not control their pace at any point during the running test. Our study design is 
similar to studies conducted during running competitions which might have 
led to differences in individual running intensities and affected their likelihood 
of developing gastrointestinal symptoms. Differences in running intensity could 
explain why the two groups experienced gastrointestinal symptoms at a similar 
rate after the running test. Our questionnaires were also mainly aimed at 
probing for symptom occurrence and not severity which could have masked 
some differences between the two groups. Overall, these factors emphasize the 
individual nature of gastrointestinal symptoms and the difficulty of accurately 
assigning individuals as asymptomatic or symptomatic. 
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6.2.2 Is intestinal ischemia the cause of increased intestinal permeability 
after running?   
Exercise reduces intestinal blood flow which may result in intestinal ischemia 
and subsequent damage to the intestinal mucosa (van Wijck et al., 2012a). Our 
data show elevated serum I-FABP concentrations after the running test which 
could be interpreted as a sign of small intestinal ischemia and enterocyte 
damage (Adriaanse et al., 2013; Hundscheid et al., 2015; van Wijck et al., 2011). 
Whether small intestinal ischemia is the cause of exercise-induced increase in 
intestinal permeability is an interesting question. A total of two studies have 
previously reported concomitant increases in plasma I-FABP levels and small 
intestinal permeability following exercise (March et al., 2017; van Wijck et al., 
2011) but contradictory findings also exist (van Wijck et al., 2014). Interpreting 
our results, it is essential to keep in mind that we employed a continuous 24-h 
intestinal permeability measurement and thus cannot distinguish between 
small intestinal and colonic permeability. Thus, our intestinal permeability 
values may not be directly comparable to the I-FABP values that represent 
mainly small intestinal damage. However, considering that the absorption of 
iohexol seems to be constant along the intestinal tract (Halme et al., 2000) and 
that comparable studies have used intestinal permeability measurement times 
ranging from 1 to 5 hours (Davison et al., 2016; JanssenDuijghuijsen et al., 2017; 
March et al., 2017; Marchbank et al., 2011; Pals et al., 1997; van Wijck et al., 2011; 
Zuhl et al., 2015), it is likely that the observed increase in intestinal permeability 
to iohexol in our study is a result of ischemia-induced damage to the small 
intestine. 
6.2.3 Does serum LPS activity contribute to gastrointestinal symptoms 
during exercise? 
Our data show that the study subjects classified as symptomatic had 
significantly higher serum LPS activity at rest than the asymptomatic subjects. 
In athletes, training-induced adaptations can impact resting blood LPS levels 
(Bosenberg et al., 1988; Lim et al., 2009) so it is possible that symptomatic 
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athletes lack adequate adaptation mechanisms and thus have chronically 
elevated LPS activity. However, whether LPS contributes to gastrointestinal 
symptoms during exercise is still under debate. Brock-Utne et al. (1988) showed 
that ultramarathon runners with high plasma LPS concentrations after running 
experienced more gastrointestinal symptoms than those with normal plasma 
LPS levels but others have not been able to show a similar correlation (Gill et 
al., 2015; Jeukendrup et al., 2000; Moncada-Jimènez et al., 2009). Hence, the 
relationship between LPS and gastrointestinal symptoms during exercise 
warrants more robust research that should considerate the individual 
differences in adaptations to LPS accumulation and clearance. 
Additionally, although multiple studies have reported increased blood LPS 
concentrations after exercise (Ashton et al., 2003; Bosenberg et al., 1988; Brock-
Utne et al., 1988; Gill et al., 2015; Jeukendrup et al., 2000; Lim et al., 2009; 
Moncada-Jimènez et al., 2009), these studies have not linked this to exercise-
induced changes in intestinal permeability. In our study, despite increased 
intestinal permeability after running, we did not observe any significant 
increases in serum LPS activity after the running test. This finding is similar to 
the only other study that has measured blood LPS concentrations 
simultaneously with a permeability marker (urinary claudin-3 concentration)  
(Yeh et al., 2013). In theory, increased intestinal permeability and LPS leakage 
into circulation could activate inflammatory processes. Our analysis show that 
running increased fecal calprotectin concentration with symptomatic athletes 
exhibiting on average twice as high values as the asymptomatic runners. Albeit 
this increase did not reach statistical significance, it indicates the activation of 
inflammatory processes in the intestinal mucosa and supports the role of 
inflammation in the development of gastrointestinal symptoms during exercise 
(Gill et al., 2015; Jeukendrup et al., 2000). 
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6.3 DCA-induced increase in macromolecular permeability 
6.3.1 Does DCA increase macromolecular permeability via activation of 
enteric nerves? 
High-fat diet increases the concentration of bile acids in the intestinal lumen 
and it has been associated with increased intestinal permeability. Multiple 
studies have previously shown the detrimental effects of hydrophobic bile acid 
DCA on the intestinal barrier function (Chadwick et al., 1979; Fihn et al., 2003; 
Goerg et al., 1980, 1983; Hughes et al., 2008; Münch et al., 2007; Stenman et al., 
2013a; Sun et al., 2004) with a few studies reporting neural mechanisms behind 
this effect (Fihn et al., 2003; Sun et al., 2004). Our data show that DCA can 
increase macromolecular permeability independent of functional enteric nerves 
suggesting the presence of other mechanisms, such as tissue damage (Stenman 
et al., 2013a) or tight junctional modifications (Raimondi et al., 2008). However, 
treating the intestinal tissues with TTX to eliminate neural activity prior to DCA 
treatment stunted the DCA-induced increase in tissue TER values. This 
indicates the involvement of some neural component. Overall, the observed 
increase in TER values is interesting because it contrasts with our previous 
findings (Stenman et al., 2013a). A possible explanation for it could be DCA-
mediated chloride secretion via cystic fibrosis transmembrane conductance 
regulator (CFTR) which collapses the lateral intercellular space (LIS) between 
adjacent enterocytes resulting in increased TER values and subsequently 
decreased paracellular permeability (Gawenis et al., 2004). This sequence may 
include a neural pathway that involves DCA-induced serotonin secretion 
(Peregrin et al., 1999; Rolfe and Levin, 1998). Nonetheless, we observed no 
changes in macromolecular permeability after DCA treatment in any of the 
intact tissues. Because we conducted this experiment in Ussing chambers, it is 
possible that the seromuscular layer presented a physical barrier that prevented 
us from seeing DCA-induced changes in permeability. This highlights some of 
the limitations associated with this method. However, considering that we 
employed a DCA concentration corresponding to that observed in fecal matter 
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of mice during high-fat feeding (Stenman et al., 2012), these findings 
corroborate the emerging hypothesis that hydrophobic bile acids may 
contribute to the barrier-disrupting effects of high-fat diet. 
 
CONCLUSIONS 
 84 
7 CONCLUSIONS 
This thesis consists of three studies where we investigated changes in intestinal 
permeability after different treatment protocols. The main findings area as 
follows: 
 
I. Commonly used chemotherapeutics, 5-FU, oxaliplatin, and 
irinotecan increase intestinal permeability to iohexol and this 
increase correlates with the clinical features of CIGT and with 
colonic damage. This study is also the first one to show that 
oxaliplatin increases intestinal permeability. 
II. Intestinal permeability to iohexol shows capability to act as a 
simple tool for objectively assessing the severity and occurrence 
of CIGT in a clinical setting. 
III. The pathophysiology of CIGT is associated with several changes 
in the composition of intestinal microbiota and in the 
metabolome. The observed changes suggest that intestinal 
dysbiosis together with increased intestinal permeability leads to 
the activation of inflammatory processes. 
IV. Running increases intestinal permeability to iohexol via 
mechanisms that involve intestinal ischemia but this increase 
does not explain the occurrence of gastrointestinal symptoms in 
individual athletes. 
V. A DCA concentration associated with high-fat feeding increases 
macromolecular permeability to fluorescein in murine small 
intestine. Although DCA elicited also a partial neural response, 
the increase in macromolecular permeability seems to be 
mediated by direct interaction with the mucosa and does not 
involve neural mechanisms.
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